

DAFTAR PUSTAKA

1. Faul M, Coronado V. Epidemiology of traumatic brain injury. In: Handbook of Clinical Neurology [Internet]. 1st ed. Elsevier B.V.; 2015. p. 3–13. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B9780444528926000015>
2. Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung Y-CC, Panchak M, et al. Estimating the global incidence of traumatic brain injury. *J Neurosurg* [Internet]. 2019 Apr;130(4):1080–97. Available from: <https://thejns.org/view/journals/j-neurosurg/130/4/article-p1080.xml>
3. Rosyidi RM, Priyanto B, Laraswati NKP, Islam AA, Hatta M, Bukhari A, et al. Characteristics and clinical outcome of traumatic brain injury in Lombok, Indonesia. *Interdiscip Neurosurg* [Internet]. 2019 Dec;18(February):100470. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2214751918303177>
4. Farzaneh E, Fattahzadeh-Ardalani G, Abbasi V, Kahnamouei-aghdam F, Molaei B, Iziy E, et al. The Epidemiology of Hospital-Referred Head Injury in Ardabil City. *Emerg Med Int* [Internet]. 2017;2017:1–5. Available from: <https://www.hindawi.com/journals/emi/2017/1439486/>
5. Mohanty S, Dey PK, Sharma HS, Singh S, Chansouria JPN, Olsson Y. Role of histamine in traumatic brain edema. An experimental study in the rat. *J Neurol Sci*. 1989;90(1):87–97.
6. Lozada A, Maegele M, Stark H, Neugebauer EMA, Panula P, Neugebauer EMA, et al. Traumatic brain injury results in mast cell increase and changes in regulation of central histamine receptors. *Neuropathol Appl Neurobiol* [Internet]. 2005 Apr;31(2):150–62. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2990.2004.00622.x>
7. Pan W, Cao Z, Liu D, Jiao Y. Protective Effect of Diphenhydramine against Traumatic Brain Injury in Rats via Modulation of Oxidative Stress and Inflammation. *Pharmacology* [Internet]. 2020;105(1–2):47–53. Available from: <https://www.karger.com/Article/FullText/502767>
8. Laufer SR. HEAD TRAUMA RELEASE OF HISTAMINE FROM DURAL MAST CELLS ALTERS BLOOD-BRAIN BARRIER: ATTENUATION WITH ZOLANTIDINE [Internet]. University of North Texas Libraries, UNT Digital Library, <https://digital.library.unt.edu>; University of North Texas; 2000. Available from: <https://digital.library.unt.edu/ark:/67531/metadc2714/>
9. Wang X, Xu J, Liang X, Gu H. Diphenhydramine exert protective action against experimental periodontitis in rats via attenuation of oxidative stress and inflammation. *Int J Clin Exp Med*. 2019;12(11):12721–30.
10. McKittrick CM, Lawrence CE, Carswell HVOO. Mast Cells Promote Blood Brain Barrier Breakdown and Neutrophil Infiltration in a Mouse Model of Focal Cerebral Ischemia. *J Cereb Blood Flow Metab* [Internet]. 2015 Apr 7;35(4):638–47. Available from: <http://dx.doi.org/10.1038/jcbfm.2014.239>
11. Hasala H, Moilanen E, Janka-Junttila M, Giembycz MA, Kankaanranta H. First-generation antihistamines diphenhydramine and chlorpheniramine reverse cytokine-afforded eosinophil survival by enhancing apoptosis. *Allergy Asthma Proc* [Internet]. 2007 Jan 1;28(1):79–86. Available from: <http://www.ingentaconnect.com/content/10.2500/aap.2007.28.2961>
12. Kempuraj D, Ahmed ME, Selvakumar GP, Thangavel R, Raikwar SP, Zaheer SA, et al. Mast Cell Activation, Neuroinflammation, and Tight Junction Protein Derangement in Acute Traumatic Brain Injury. *Mediators Inflamm* [Internet]. 2020 Jun 24;2020:1–12. Available from: <https://www.hindawi.com/journals/mi/2020/4243953/>
13. Moretti R, Chhor V, Bettati D, Banino E, De Lucia S, Le Charpentier T, et al. Contribution of mast cells to injury mechanisms in a mouse model of pediatric traumatic brain injury. *J Neurosci Res* [Internet]. 2016 Dec;94(12):1546–60. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jnr.23911>
14. Kline T. Art Therapy for Individuals With Traumatic Brain Injury: A Comprehensive Neurorehabilitation-Informed Approach to Treatment. *Art Ther*. 2016 Apr 2;33(2):67–73.
15. Pearn ML, Niesman IR, Egawa J, Sawada A, Almenar-Queralt A, Shah SB, et al. Pathophysiology Associated with Traumatic Brain Injury: Current Treatments and Potential Novel Therapeutics. *Cell Mol Neurobiol*. 2017 May 6;37(4):571–85.
16. Silver, Jonathan M, McAllister, Thomas W, Yudofsky, Stuart C. *Textbook of Traumatic Brain Injury*. 2011.
17. Frieden TR, Houry D, Baldwin G. *Traumatic Brain Injury In the United States: Epidemiology and Rehabilitation*. 2015.
18. Sekeon SAS, Maja J, Kembangan MAHN. Executive function disorder in acute traumatic brain injury in Manado, Indonesia [Internet]. Vol. 4, www.gimedph.org. 2015. Available from: www.gimedph.org
19. Ladak AA, Enam SA, Ibrahim MT. A Review of the Molecular Mechanisms of Traumatic Brain Injury. *World Neurosurg*. 2019 Nov;131:126–32.
20. Obenaus A. Traumatic Brain Injury. In: *Encyclopedia of Mental Health*. Elsevier; 2016. p. 329–40.
21. Department of Veterans Affairs, Department of Defense. VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF CONCUSSION-MILD TRAUMATIC BRAIN INJURY [Internet]. 2016. Available from: www.tricare.mil
22. Ashley MJ, Hovda DA. *Traumatic Brain Injury*. Ashley MJ, Hovda DA, editors. CRC Press; 2017.
23. Nizamutdinov D, Shapiro L. Overview of Traumatic Brain Injury: An Immunological Context. *Brain Sci*. 2017 Jan 23;7(12):11.
24. Teasdale GM, Murray GD, Nicoll JAR. The association between APOE ε4, age and outcome after head injury: a prospective cohort study. *Brain*. 2005 Nov 1;128(11):2556–61.
25. Blumbergs PC, Jones NR, North JB. Diffuse axonal injury in head trauma. *J Neurol Neurosurg Psychiatry*. 1989 Jul 1;52(7):838–41.
26. McGinn MJ, Povlishock JT. Pathophysiology of Traumatic Brain Injury. *Neurosurg Clin N Am*. 2016 Oct;27(4):397–407.

27. Fujisawa H, Maxwell WL, Graham DI, Reasdale GM, Bullock R. Focal Microvascular Occlusion After Acute Subdural Haematoma in the Rat: a Mechanism for Ischaemic Damage and Brain Swelling? In: Brain Edema IX. Vienna: Springer Vienna; 1994. p. 193–6.
28. Kurland D, Hong C, Aarabi B, Gerzanich V, Simard JM. Hemorrhagic Progression of a Contusion after Traumatic Brain Injury: A Review. *J Neurotrauma*. 2012 Jan;29(1):19–31.
29. Povlishock JT, Kontos HA. The role of oxygen radicals in the pathobiology of traumatic brain injury. *Hum Cell*. 1992 Dec;5(4):345–53.
30. Mondello S, Jeromin A, Buki A, Bullock R, Czeiter E, Kovacs N, et al. Glial Neuronal Ratio: A Novel Index for Differentiating Injury Type in Patients with Severe Traumatic Brain Injury. *J Neurotrauma*. 2012 Apr 10;29(6):1096–104.
31. Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, et al. Elevated Levels of Serum Glial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated With Intracranial Lesions and Neurosurgical Intervention. *Ann Emerg Med*. 2012 Jun;59(6):471–83.
32. Wang KKW, Yang Z, Yue JK, Zhang Z, Winkler EA, Puccio AM, et al. Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study. *J Neurotrauma*. 2016 Jul;33(13):1270–7.
33. Yuh EL, Cooper SR, Mukherjee P, Yue JK, Lingsma HF, Gordon WA, et al. Diffusion Tensor Imaging for Outcome Prediction in Mild Traumatic Brain Injury: A TRACK-TBI Study. *J Neurotrauma*. 2014 Sep;31(17):1457–77.
34. Farkas O. Mechanoporation Induced by Diffuse Traumatic Brain Injury: An Irreversible or Reversible Response to Injury? *J Neurosci*. 2006 Mar 22;26(12):3130–40.
35. Farkas O, Povlishock JT. Cellular and subcellular change evoked by diffuse traumatic brain injury: a complex web of change extending far beyond focal damage. In 2007. p. 43–59.
36. Stoica BA, Byrnes KR, Faden AI. Cell Cycle Activation and CNS Injury. *Neurotox Res*. 2009 Oct 21;16(3):221–37.
37. Stoica BA, Faden AI. Cell death mechanisms and modulation in traumatic brain injury. *Neurotherapeutics* [Internet]. 2010 Jan;7(1):3–12. Available from: <http://link.springer.com/10.1016/j.nurt.2009.10.023>
38. Adams JH, Doyle D, Ford I, Gennarelli TA, Graham DI, McLellan DR. Diffuse axonal injury in head injury: Definition, diagnosis and grading. *Histopathology*. 1989 Jul;15(1):49–59.
39. BLUMBERGS PC, SCOTT G, VIS JM, WAINWRIGHT H, SIMPSON DA, McLEAN AJ. Topography of Axonal Injury as Defined by Amyloid Precursor Protein and the Sector Scoring Method in Mild and Severe Closed Head Injury. *J Neurotrauma*. 1995 Aug;12(4):565–72.
40. Adams JH, Graham DI, Murray LS, Scott G. Diffuse axonal injury due to nonmissile head injury in humans: An analysis of 45 cases. *Ann Neurol*. 1982 Dec;12(6):557–63.
41. Povlishock JT, Becker DP, Cheng CLY, Vaughan GW. Axonal Change in Minor Head Injury. *J Neuropathol Exp Neurol*. 1983 May;42(3):225–42.
42. Buki A, Povlishock JT. All roads lead to disconnection? – Traumatic axonal injury revisited. *Acta Neurochir (Wien)*. 2006 Feb 20;148(2):181–94.
43. Smith DH, Hicks R, Povlishock JT. Therapy Development for Diffuse Axonal Injury. *J Neurotrauma*. 2013 Mar;30(5):307–23.
44. Buki A, Siman R, Trojanowski JQ, Povlishock JT. The Role of Calpain-Mediated Spectrin Proteolysis in Traumatologically Induced Axonal Injury. *J Neuropathol Exp Neurol*. 1999 Apr;58(4):365–75.
45. Povlishock JT, Erb DE, Astruc J. Axonal response to traumatic brain injury: reactive axonal change, deafferentation, and neuroplasticity. *J Neurotrauma*. 1992 Mar;9 Suppl 1:S189–200.
46. Wang J, Fox MA, Povlishock JT. Diffuse Traumatic Axonal Injury in the Optic Nerve Does Not Elicit Retinal Ganglion Cell Loss. *J Neuropathol Exp Neurol*. 2013 Aug 1;72(8):768–81.
47. Niogi SN, Mukherjee P, Ghajar J, Johnson C, Kolster RA, Sarkar R, et al. Extent of Microstructural White Matter Injury in Postconcussive Syndrome Correlates with Impaired Cognitive Reaction Time: A 3T Diffusion Tensor Imaging Study of Mild Traumatic Brain Injury. *Am J Neuroradiol*. 2008 May;29(5):967–73.
48. Spitz G, Maller JJ, Ng A, O’Sullivan R, Ferris NJ, Ponsford JL. Detecting Lesions after Traumatic Brain Injury Using Susceptibility Weighted Imaging: A Comparison with Fluid-Attenuated Inversion Recovery and Correlation with Clinical Outcome. *J Neurotrauma*. 2013 Dec 15;30(24):2038–50.
49. Benson RR, Gattu R, Sewick B, Kou Z, Zakariah N, Cavanaugh JM, et al. Detection of hemorrhagic and axonal pathology in mild traumatic brain injury using advanced MRI: Implications for neurorehabilitation. *NeuroRehabilitation*. 2012 Sep 17;31(3):261–79.
50. Marmarou CR, Walker SA, Davis CL, Povlishock JT. Quantitative Analysis of the Relationship between Intra-Axonal Neurofilament Compaction and Impaired Axonal Transport following Diffuse Traumatic Brain Injury. *J Neurotrauma*. 2005 Oct;22(10):1066–80.
51. REEVES T, PHILLIPS L, POVLISHOCK J. Myelinated and unmyelinated axons of the corpus callosum differ in vulnerability and functional recovery following traumatic brain injury. *Exp Neurol*. 2005 Nov;196(1):126–37.
52. Nakamura T, Hillary FG, Biswal BB. Resting Network Plasticity Following Brain Injury. *PLoS One*. 2009 Dec 14;4(12):e8220.
53. Kasahara M, Menon DK, Salmund CH, Outtrim JG, Taylor Tavares JV, Carpenter TA, et al. Altered functional connectivity in the motor network after traumatic brain injury. *Neurology*. 2010 Jul 13;75(2):168–76.
54. Kasahara M, Menon DK, Salmund CH, Outtrim JG, Tavares JVT, Carpenter TA, et al. Traumatic brain injury alters the functional brain network mediating working memory. *Brain Inj*. 2011 Nov 20;25(12):1170–87.
55. McDonald BC, Saykin AJ, McAllister TW. Functional MRI of mild traumatic brain injury (mTBI): progress and perspectives from the first decade of studies. *Brain Imaging Behav*. 2012 Jun 18;6(2):193–207.
56. Sharp DJ, Scott G, Leech R. Network dysfunction after traumatic brain injury. *Nat Rev Neurol*. 2014 Mar 11;10(3):156–66.
57. Cortez SC, McIntosh TK, Noble LJ. Experimental fluid percussion brain injury: vascular disruption and neuronal and glial alterations. *Brain Res*. 1989 Mar;482(2):271–82.
58. DIETRICH WD, ALONSO O, BUSTO R, GINSBERG MD. Widespread Metabolic Depression and Reduced

- Somatosensory Circuit Activation Following Traumatic Brain Injury in Rats. *J Neurotrauma*. 1994 Dec;11(6):629–40.
59. Dietrich WD, Alonso O, Busto R, Globus MY-T, Ginsberg MD. Post-traumatic brain hypothermia reduces histopathological damage following concussive brain injury in the rat. *Acta Neuropathol*. 1994 Mar;87(3):250–8.
 60. Colicos MA, Dixon CE, Dash PK. Delayed, selective neuronal death following experimental cortical impact injury in rats: possible role in memory deficits. *Brain Res*. 1996 Nov;739(1–2):111–9.
 61. Jenkins LW, Moszynski K, Lyeth BG, Lewelt W, DeWitt DS, Allen A, et al. Increased vulnerability of the mildly traumatized rat brain to cerebral ischemia: the use of controlled secondary ischemia as a research tool to identify common or different mechanisms contributing to mechanical and ischemic brain injury. *Brain Res*. 1989 Jan;477(1–2):211–24.
 62. Ballanyi K, Grafe P, ten Bruggencate G. Ion activities and potassium uptake mechanisms of glial cells in guinea-pig olfactory cortex slices. *J Physiol*. 1987 Jan 1;382(1):159–74.
 63. Kuffler SW. The Ferrier Lecture - Neuroglial cells: physiological properties and a potassium mediated effect of neuronal activity on the glial membrane potential. *Proc R Soc London Ser B Biol Sci*. 1967 Jun 6;168(1010):1–21.
 64. Paulson OB, Newman EA. Does the Release of Potassium from Astrocyte Endfeet Regulate Cerebral Blood Flow? *Science (80-)*. 1987 Aug 21;237(4817):896–8.
 65. Moody WJ, Futamachi KJ, Prince DA. Extracellular potassium activity during epileptogenesis. *Exp Neurol*. 1974 Feb;42(2):248–63.
 66. Sybert GW, Ward AA. Changes in extracellular potassium activity during neocortical propagated seizures. *Exp Neurol*. 1974 Oct;45(1):19–41.
 67. D'Ambrosio R, Maris DO, Grady MS, Winn HR, Janigro D. Impaired K⁺ Homeostasis and Altered Electrophysiological Properties of Post-Traumatic Hippocampal Glia. *J Neurosci*. 1999 Sep 15;19(18):8152–62.
 68. Astrup J, Rehncrona S, Siesjö BK. The increase in extracellular potassium concentration in the ischemic brain in relation to the preischemic functional activity and cerebral metabolic rate. *Brain Res*. 1980 Oct;199(1):161–74.
 69. Hansen AJ. Extracellular Potassium Concentration in Juvenile and Adult Rat Brain Cortex during Anoxia. *Acta Physiol Scand*. 1977 Apr;99(4):412–20.
 70. Hansen AJ. The extracellular potassium concentration in brain cortex following ischemia in hypo- and hyperglycemic rats. *Acta Physiol Scand*. 1978 Mar;102(3):324–9.
 71. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep Drives Metabolite Clearance from the Adult Brain. *Science (80-)*. 2013 Oct 18;342(6156):373–7.
 72. Prince DA, Lux HD, Neher E. Measurement of extracellular potassium activity in cat cortex. *Brain Res*. 1973 Feb;50(2):489–95.
 73. Sugaya E, Takato M, Noda Y. Neuronal and glial activity during spreading depression in cerebral cortex of cat. *J Neurophysiol*. 1975 Jul 1;38(4):822–41.
 74. Bartnik BL, Lee SM, Hovda DA, Sutton RL. The Fate of Glucose during the Period of Decreased Metabolism after Fluid Percussion Injury: A ¹³C NMR Study. *J Neurotrauma*. 2007 Jul;24(7):1079–92.
 75. Bartnik-Olson BL, Harris NG, Shijo K, Sutton RL. Insights into the metabolic response to traumatic brain injury as revealed by ¹³C NMR spectroscopy. *Front Neuroenergetics*. 2013;5.
 76. Bartnik BL, Sutton RL, Fukushima M, Harris NG, Hovda DA, Lee SM. Upregulation of Pentose Phosphate Pathway and Preservation of Tricarboxylic Acid Cycle Flux after Experimental Brain Injury. *J Neurotrauma*. 2005 Oct;22(10):1052–65.
 77. Maeda T, Lee SM, Hovda DA. Restoration of Cerebral Vasoreactivity by an L-Type Calcium Channel Blocker following Fluid Percussion Brain Injury. *J Neurotrauma*. 2005 Jul;22(7):763–71.
 78. Martin NA, Patwardhan R V., Alexander MJ, Africk CZ, Lee JH, Shalmon E, et al. Characterization of cerebral hemodynamic phases following severe head trauma: hypoperfusion, hyperemia, and vasospasm. *J Neurosurg*. 1997 Jul;87(1):9–19.
 79. Tavazzi B, Vagnozzi R, Signoretti S, Amorini AM, Finocchiaro A, Cimatti M, et al. TEMPORAL WINDOW OF METABOLIC BRAIN VULNERABILITY TO CONCUSSIONS. *Neurosurgery*. 2007 Aug 1;61(2):390–6.
 80. Vagnozzi R, Tavazzi B, Signoretti S, Amorini AM, Belli A, Cimatti M, et al. TEMPORAL WINDOW OF METABOLIC BRAIN VULNERABILITY TO CONCUSSIONS. *Neurosurgery*. 2007 Aug 1;61(2):379–89.
 81. Lifshitz J, Sullivan PG, Hovda DA, Wieloch T, McIntosh TK. Mitochondrial damage and dysfunction in traumatic brain injury. *Mitochondrion*. 2004 Sep;4(5–6):705–13.
 82. Aoyama N, Lee SM, Moro N, Hovda DA, Sutton RL. Duration of ATP reduction affects extent of CA1 cell death in rat models of fluid percussion injury combined with secondary ischemia. *Brain Res*. 2008 Sep;1230:310–9.
 83. Kawamata T, Katayama Y, Hovda DA, Yoshino A, Becker DP. Lactate accumulation following concussive brain injury: the role of ionic fluxes induced by excitatory amino acids. *Brain Res*. 1995 Mar;674(2):196–204.
 84. Osteen CL, Moore AH, Prins ML, Hovda DA. Age-Dependency of 45 Calcium Accumulation Following Lateral Fluid Percussion: Acute and Delayed Patterns. *J Neurotrauma*. 2001 Feb;18(2):141–62.
 85. Xing G, Ren M, O'Neill JT, Verma A, Watson WD. Controlled cortical impact injury and craniotomy result in divergent alterations of pyruvate metabolizing enzymes in rat brain. *Exp Neurol*. 2012 Mar;234(1):31–8.
 86. Bergsneider M, Hovda DA, Shalmon E, Kelly DF, Vespa PM, Martin NA, et al. Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. *J Neurosurg*. 1997 Feb;86(2):241–51.
 87. Bergsneider M, Hovda DA, McArthur DL, Etchepare M, Huang S-C, Sehati N, et al. Metabolic Recovery Following Human Traumatic Brain Injury Based on FDG-PET: Time Course and Relationship to Neurological Disability. *J Head Trauma Rehabil*. 2001 Apr;16(2):135–48.
 88. BERGSNEIDER M, HOVDA DA, LEE SM, KELLY DF, McARTHUR DL, VESPA PM, et al. Dissociation of Cerebral Glucose Metabolism and Level of Consciousness During the Period of Metabolic Depression Following Human Traumatic Brain Injury. *J Neurotrauma*. 2000 May;17(5):389–401.
 89. Prins ML, Hales A, Reger M, Giza CC, Hovda DA. Repeat Traumatic Brain Injury in the Juvenile Rat Is Associated with Increased Axonal Injury and Cognitive Impairments. *Dev Neurosci*. 2010;
 90. Prins ML, Alexander D, Giza CC, Hovda DA. Repeated Mild Traumatic Brain Injury: Mechanisms of Cerebral Vulnerability. *J Neurotrauma*. 2013 Jan;30(1):30–8.

91. Kumar A, Loane DJ. Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention. *Brain Behav Immun* [Internet]. 2012 Nov;26(8):1191–201. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S088915911200150X>
92. Navarro A, Gómez C, Sánchez-Pino M-J, González H, Bández MJ, Boveris AD, et al. Vitamin E at high doses improves survival, neurological performance, and brain mitochondrial function in aging male mice. *Am J Physiol Integr Comp Physiol* [Internet]. 2005 Nov;289(5):R1392–9. Available from: <https://www.physiology.org/doi/10.1152/ajpregu.00834.2004>
93. Moorthy K, Yadav UCS, Siddiqui MR, Mantha AK, Basir SF, Sharma D, et al. Effect of Hormone Replacement Therapy in Normalizing Age Related Neuronal Markers in Different Age Groups of Naturally Menopausal Rats. *Biogerontology* [Internet]. 2005 Nov;6(5):345–56. Available from: <http://link.springer.com/10.1007/s10522-005-4810-6>
94. Acosta SA, Tajiri N, de la Pena I, Bastawrous M, Sanberg PR, Kaneko Y, et al. Alpha-Synuclein as a Pathological Link Between Chronic Traumatic Brain Injury and Parkinson's Disease. *J Cell Physiol*. 2015 May 28;230(5):1024–32.
95. Hernandez-Ontiveros DG, Tajiri N, Acosta S, Giunta B, Tan J, Borlongan C V. Microglia Activation as a Biomarker for Traumatic Brain Injury. *Front Neurol*. 2013;4.
96. Acosta SA, Tajiri N, Shinozuka K, Ishikawa H, Grimmig B, Diamond D, et al. Long-Term Upregulation of Inflammation and Suppression of Cell Proliferation in the Brain of Adult Rats Exposed to Traumatic Brain Injury Using the Controlled Cortical Impact Model. *PLoS One*. 2013 Jan 3;8(1):e53376.
97. Xu H-M. Th1 cytokine-based immunotherapy for cancer. *Hepatobiliary Pancreat Dis Int*. 2014 Oct;13(5):482–94.
98. Myer DJ. Essential protective roles of reactive astrocytes in traumatic brain injury. *Brain*. 2006 Jul 15;129(10):2761–72.
99. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. *Nature*. 2015 Jul 16;523(7560):337–41.
100. Rock KL, Kono H. The Inflammatory Response to Cell Death. *Annu Rev Pathol Mech Dis*. 2008 Feb 1;3(1):99–126.
101. Mathew P, Graham DI, Bullock R, Maxwell W, McCulloch J, Teasdale G. Focal Brain Injury: Histological Evidence of Delayed Inflammatory Response in a New Rodent Model of Focal Cortical Injury. In: *Brain Edema IX*. Vienna: Springer Vienna; 1994. p. 428–30.
102. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. *Trends Neurosci* [Internet]. 1996 Aug;19(8):312–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/0166223696100497>
103. Streit WJ. Microglial Response to Brain Injury: A Brief Synopsis. *Toxicol Pathol*. 2000 Jan 2;28(1):28–30.
104. Nakajima K, Kohsaka S. Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System. *Curr Drug Target -Cardiovascular Hematol Disord*. 2004 Mar 1;4(1):65–84.
105. Gehrman J, Matsumoto Y, Kreutzberg GW. Microglia: Intrinsic immune effector cell of the brain. *Brain Res Rev*. 1995 Mar;20(3):269–87.
106. Benveniste EN. Cytokine Actions in the Central Nervous System. *Cytokine Growth Factor Rev*. 1998 Dec;9(3–4):259–75.
107. Witcher KG, Eiferman DS, Godbout JP. Priming the Inflammatory Pump of the CNS after Traumatic Brain Injury. *Trends Neurosci*. 2015 Oct;38(10):609–20.
108. Holmin S, Söderlund J, Biberfeld P, Mathiesen T. Intracerebral Inflammation after Human Brain Contusion. *Neurosurgery* [Internet]. 1998 Feb 1;42(2):291–8. Available from: <https://academic.oup.com/neurosurgery/article/42/2/291/2856417>
109. Royo NC, Wahl F, Stutzmann J-M. Kinetics of polymorphonuclear neutrophil infiltration after a traumatic brain injury in rat. *Neuroreport*. 1999 Apr;10(6):1363–7.
110. Habgood MD, Bye N, Dziegielewska KM, Ek CJ, Lane MA, Potter A, et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. *Eur J Neurosci*. 2007 Jan 12;25(1):231–8.
111. Scholz M, Cinatl J, Schädel-Höpfner M, Windolf J. Neutrophils and the blood–brain barrier dysfunction after trauma. *Med Res Rev*. 2007 May;27(3):401–16.
112. Semple BD, Bye N, Ziebell JM, Morganti-Kossmann MC. Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury. *Neurobiol Dis* [Internet]. 2010 Nov;40(2):394–403. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0969996110002111>
113. Ransohoff RM, Tani M. Do chemokines mediate leukocyte recruitment in post-traumatic CNS inflammation? *Trends Neurosci*. 1998 Apr;21(4):154–9.
114. Hausmann EH., Berman NE., Wang Y-Y, Meara JB, Wood GW, Klein RM. Selective chemokine mRNA expression following brain injury. *Brain Res*. 1998 Mar;788(1–2):49–59.
115. CLARK RSB, SCHIDING JK, KACZOROWSKI SL, MARION DW, KOCHANEK PM. Neutrophil Accumulation After Traumatic Brain Injury in Rats: Comparison of Weight Drop and Controlled Cortical Impact Models. *J Neurotrauma* [Internet]. 1994 Oct;11(5):499–506. Available from: <http://www.liebertpub.com/doi/10.1089/neu.1994.11.499>
116. Kossmann T, Hans VHJ, Imhof H-G, Stocker R, Grob P, Trentz O, et al. INTRATHECAL AND SERUM INTERLEUKIN-6 AND THE ACUTE-PHASE RESPONSE IN PATIENTS WITH SEVERE TRAUMATIC BRAIN INJURIES. *Shock*. 1995 Nov;4(5):311–7.
117. Kossmann T, Stahel PF, Lenzlinger PM, Redl H, Dubs RW, Trentz O, et al. Interleukin-8 Released into the Cerebrospinal Fluid after Brain Injury is Associated with Blood–Brain Barrier Dysfunction and Nerve Growth Factor Production. *J Cereb Blood Flow Metab*. 1997 Mar 31;17(3):280–9.
118. Morganti-Kossmann MC, Lenzlinger PM, Hans V, Stahel P, Csuka E, Ammann E, et al. Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. *Mol Psychiatry* [Internet]. 1997 Mar 18;2(2):133–6. Available from: <http://www.nature.com/articles/4000227>
119. Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF- α , TGF- β 1 and blood–brain barrier function. *J Neuroimmunol* [Internet]. 1999 Nov;101(2):211–21. Available from:

- <https://linkinghub.elsevier.com/retrieve/pii/S0165572899001484>
120. Fassbender K, Schneider S, Bertsch T, Schlueter D, Fatar M, Ragoschke A, et al. Temporal profile of release of interleukin-1 β in neurotrauma. *Neurosci Lett*. 2000 Apr;284(3):135–8.
 121. Maier B, Schwerdtfeger K, Mautes A, Holanda M, Müller M, Stuedel WI, et al. DIFFERENTIAL RELEASE OF INTERLEUKINES 6, 8, AND 10 IN CEREBROSPINAL FLUID AND PLASMA AFTER TRAUMATIC BRAIN INJURY. *Shock*. 2001 Jun;15(6):421–6.
 122. McIntosh TK, Lenzlinger PM, Morganti-Kossmann M-C, Laurer HL. The Duality of the Inflammatory Response to Traumatic Brain Injury. *Mol Neurobiol* [Internet]. 2001;24(1–3):169–82. Available from: <http://link.springer.com/10.1385/MN:24:1-3:169>
 123. Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T. Inflammatory response in acute traumatic brain injury: a double-edged sword. *Curr Opin Crit Care* [Internet]. 2002 Apr;8(2):101–5. Available from: <http://journals.lww.com/00075198-200204000-00002>
 124. Yatsiv I, Morganti-Kossmann MC, Perez D, Dinarello CA, Novick D, Rubinstein M, et al. Elevated Intracranial IL-18 in Humans and Mice after Traumatic Brain Injury and Evidence of Neuroprotective Effects of IL-18—Binding Protein after Experimental Closed Head Injury. *J Cereb Blood Flow Metab*. 2002 Aug 31;22(8):971–8.
 125. Hutchinson PJ, O’Connell MT, Rothwell NJ, Hopkins SJ, Nortje J, Carpenter KLH, et al. Inflammation in Human Brain Injury: Intracerebral Concentrations of IL-1 α , IL-1 β , and Their Endogenous Inhibitor IL-1ra. *J Neurotrauma*. 2007 Oct;24(10):1545–57.
 126. Utagawa A, Truettner JS, Dietrich WD, Bramlett HM. Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in rats. *Exp Neurol*. 2008 May;211(1):283–91.
 127. Minami M, Kuraishi Y, Satoh M. Effects of kainic acid on messenger RNA levels of IL-1 β , IL-6, TNF α and LIF in the rat brain. *Biochem Biophys Res Commun*. 1991 Apr;176(2):593–8.
 128. Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC, et al. Tumor necrosis factor-alpha expression in ischemic neurons. *Stroke* [Internet]. 1994 Jul;25(7):1481–8. Available from: <https://www.ahajournals.org/doi/10.1161/01.STR.25.7.1481>
 129. Chizzolini C, Dayer J-M, Miossec P. Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance? *Arthritis Res Ther*. 2009;11(5):246.
 130. Helmy A, Carpenter KL, Menon DK, Pickard JD, Hutchinson PJ. The Cytokine Response to Human Traumatic Brain Injury: Temporal Profiles and Evidence for Cerebral Parenchymal Production. *J Cereb Blood Flow Metab*. 2011 Feb 18;31(2):658–70.
 131. Trahanas DM, Cuda CM, Perlman H, Schwulst SJ. Differential Activation of Infiltrating Monocyte-Derived Cells After Mild and Severe Traumatic Brain Injury. *Shock*. 2015 Mar;43(3):255–60.
 132. Rhodes J. Peripheral immune cells in the pathology of traumatic brain injury? *Curr Opin Crit Care*. 2011 Apr;17(2):122–30.
 133. Tobin RP, Mukherjee S, Kain JM, Rogers SK, Henderson SK, Motal HL, et al. Traumatic brain injury causes selective, CD74-dependent peripheral lymphocyte activation that exacerbates neurodegeneration. *Acta Neuropathol Commun*. 2014 Oct 20;2:143.
 134. Schwulst SJ, Trahanas DM, Saber R, Perlman H. Traumatic brain injury–induced alterations in peripheral immunity. *J Trauma Acute Care Surg*. 2013 Nov;75(5):780–8.
 135. Rasouli J, Lekhraj R, Ozbalik M, Lalezari P, Casper D. Brain-Spleen Inflammatory Coupling: A Literature Review. *Einstein J Biol Med*. 2016 Mar 2;27(2):74.
 136. Schwartz M, Deczkowska A. Neurological Disease as a Failure of Brain–Immune Crosstalk: The Multiple Faces of Neuroinflammation. *Trends Immunol*. 2016 Oct;37(10):668–79.
 137. Schwartz M. Helping The Body To Cure Itself: Immune Modulation By Therapeutic Vaccination For Spinal Cord Injury. *J Spinal Cord Med*. 2003 Jan 4;26(sup1):S6–10.
 138. Foley LM, Hitchens TK, Ho C, Janesko-Feldman KL, Melick JA, Bayir H, et al. Magnetic Resonance Imaging Assessment of Macrophage Accumulation in Mouse Brain after Experimental Traumatic Brain Injury. *J Neurotrauma*. 2009 Sep;26(9):1509–19.
 139. Soares H, Hicks R, Smith D, McIntosh T. Inflammatory leukocytic recruitment and diffuse neuronal degeneration are separate pathological processes resulting from traumatic brain injury. *J Neurosci* [Internet]. 1995 Dec 1;15(12):8223–33. Available from: <https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.15-12-08223.1995>
 140. Kenne E, Erlandsson A, Lindbom L, Hillered L, Clausen F. Neutrophil depletion reduces edema formation and tissue loss following traumatic brain injury in mice. *J Neuroinflammation*. 2012 Dec 23;9(1):17.
 141. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. *Stroke* [Internet]. 1992 Sep;23(9):1367–79. Available from: <https://www.ahajournals.org/doi/10.1161/01.STR.23.9.1367>
 142. Lucchesi BR, Mullane KM. Leukocytes and Ischemia-Induced Myocardial Injury. *Annu Rev Pharmacol Toxicol*. 1986 Apr;26(1):201–24.
 143. Langer HF, Chavakis T. Leukocyte - endothelial interactions in inflammation. *J Cell Mol Med* [Internet]. 2009 Jul;13(7):1211–20. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1582-4934.2009.00811.x>
 144. Burke-Gaffey A, Keenan AK. Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 α/β , tumor necrosis factor- α and interferon- γ . *Immunopharmacology*. 1993 Jan;25(1):1–9.
 145. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. *Stroke*. 1991 Jul;22(7):877–83.
 146. Schwartz M, Yoles E. Macrophages and dendritic cells treatment of spinal cord injury: from the bench to the clinic. In 2005. p. 147–50.
 147. Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. *Best Pract Res Clin Anaesthesiol*. 2010 Dec;24(4):551–62.
 148. Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation. *Exp Neurol*. 2010 Sep;225(1):9–17.
 149. Jin X, Ishii H, Bai Z, Itokazu T, Yamashita T. Temporal Changes in Cell Marker Expression and Cellular Infiltration in a Controlled Cortical Impact Model in Adult Male C57BL/6 Mice. *PLoS One*. 2012 Jul

- 24;7(7):e41892.
150. Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, et al. Microglia/Macrophage Polarization Dynamics Reveal Novel Mechanism of Injury Expansion After Focal Cerebral Ischemia. *Stroke*. 2012 Nov;43(11):3063–70.
 151. Rolls A, Shechter R, London A, Segev Y, Jacob-Hirsch J, Amariglio N, et al. Two Faces of Chondroitin Sulfate Proteoglycan in Spinal Cord Repair: A Role in Microglia/Macrophage Activation. *PLoS Med*. 2008 Aug 19;5(8):e171.
 152. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. *Nat Rev Neurosci*. 2015 Jun 20;16(6):358–72.
 153. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep*. 2014 Mar 3;6.
 154. Verma S, Nakaoko R, Dohgu S, Banks WA. Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. *Brain Behav Immun*. 2006 Sep;20(5):449–55.
 155. Jang E, Lee S, Kim J, Kim J, Seo J, Lee W, et al. Secreted protein lipocalin-2 promotes microglial M1 polarization. *FASEB J*. 2013 Mar 3;27(3):1176–90.
 156. Rocher C, Singla DK. SMAD-PI3K-Akt-mTOR Pathway Mediates BMP-7 Polarization of Monocytes into M2 Macrophages. *PLoS One*. 2013 Dec 20;8(12):e84009.
 157. Starosom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, et al. Galectin-1 Deactivates Classically Activated Microglia and Protects from Inflammation-Induced Neurodegeneration. *Immunity*. 2012 Aug;37(2):249–63.
 158. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. *Nat Immunol*. 2010 Oct 20;11(10):889–96.
 159. Mukherjee S, Katki K, Arisi GM, Foresti ML, Shapiro LA. Early TBI-Induced Cytokine Alterations are Similarly Detected by Two Distinct Methods of Multiplex Assay. *Front Mol Neurosci*. 2011;4.
 160. Ni K, O'Neill H. The role of dendritic cells in T cell activation. *Immunol Cell Biol*. 1997 Jun;75(3):223–30.
 161. Pozzi L-AM, Maciaszek JW, Rock KL. Both Dendritic Cells and Macrophages Can Stimulate Naive CD8 T Cells In Vivo to Proliferate, Develop Effector Function, and Differentiate into Memory Cells. *J Immunol*. 2005 Aug 15;175(4):2071–81.
 162. Morganti JM, Riparip L-K, Rosi S. Call Off the Dog(ma): M1/M2 Polarization Is Concurrent following Traumatic Brain Injury. Borlongan C V, editor. *PLoS One* [Internet]. 2016 Jan 25;11(1):e0148001. Available from: <https://dx.plos.org/10.1371/journal.pone.0148001>
 163. Kumar A, Alvarez-Croda D-M, Stoica BA, Faden AI, Loane DJ. Microglial/Macrophage Polarization Dynamics following Traumatic Brain Injury. *J Neurotrauma* [Internet]. 2016 Oct;33(19):1732–50. Available from: <http://www.liebertpub.com/doi/10.1089/neu.2015.4268>
 164. Ansari MA. Temporal profile of M1 and M2 responses in the hippocampus following early 24 h of neurotrauma. *J Neurol Sci*. 2015 Oct;357(1–2):41–9.
 165. Lorente L. Biomarkers Associated with the Outcome of Traumatic Brain Injury Patients. *Brain Sci*. 2017 Oct 27;7(12):142.
 166. Cherry JD, Tripodis Y, Alvarez VE, Huber B, Kiernan PT, Daneshvar DH, et al. Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. *Acta Neuropathol Commun*. 2016 Dec 28;4(1):112.
 167. Kelso ML, Gendelman HE. Bridge between neuroimmunity and traumatic brain injury. *Curr Pharm Des*. 2014;20(26):4284–98.
 168. Gyoneva S, Kim D, Katsumoto A, Kokiko-Cochran ON, Lamb BT, Ransohoff RM. Ccr2 deletion dissociates cavity size and tau pathology after mild traumatic brain injury. *J Neuroinflammation*. 2015 Dec 3;12(1):228.
 169. Gelderblom M, Arunachalam P, Magnus T. P⁺ T cells as early sensors of tissue damage and mediators of secondary neurodegeneration. *Front Cell Neurosci*. 2014 Nov 5;8.
 170. Sobottka B, Harrer MD, Ziegler U, Fischer K, Wiendl H, Hünig T, et al. Collateral Bystander Damage by Myelin-Directed CD8⁺ T Cells Causes Axonal Loss. *Am J Pathol*. 2009 Sep;175(3):1160–6.
 171. Melzer N, Meuth SG, Wiendl H. CD8⁺ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. *FASEB J*. 2009 Nov 30;23(11):3659–73.
 172. Serpe CJ, Coers S, Sanders VM, Jones KJ. CD4⁺ T, but not CD8⁺ or B, lymphocytes mediate facial motoneuron survival after facial nerve transection. *Brain Behav Immun*. 2003 Oct;17(5):393–402.
 173. Schwartz M, Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. *Nat Rev Neurol*. 2010 Jul 8;6(7):405–10.
 174. Cohen IR. The cognitive paradigm and the immunological homunculus. *Immunol Today*. 1992 Jan;13(12):490–4.
 175. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. *Nat Med*. 1999 Jan;5(1):49–55.
 176. Bradl M, Bauer J, Flügel A, Wekerle H, Lassmann H. Complementary Contribution of CD4 and CD8 T Lymphocytes to T-Cell Infiltration of the Intact and the Degenerative Spinal Cord. *Am J Pathol*. 2005 May;166(5):1441–50.
 177. Martin R, Jaraquemada D, Flerlage M, Richert J, Whitaker J, Long EO, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. *J Immunol*. 1990 Jul 15;145(2):540–8.
 178. Sakaguchi S. Naturally arising Foxp3-expressing CD25⁺CD4⁺ regulatory T cells in immunological tolerance to self and non-self. *Nat Immunol*. 2005 Apr 22;6(4):345–52.
 179. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. *Nat Immunol*. 2003 Apr 3;4(4):330–6.
 180. Simon GJ Ben, Hovda DA, Harris NG, Gomez-Pinilla F, Goldberg RA. Traumatic Brain Injury Induced Neuroprotection of Retinal Ganglion Cells to Optic Nerve Crush. *J Neurotrauma*. 2006 Jul;23(7):1072–82.
 181. Fisher J, Levkovitch-Verbin H, Schori H, Yoles E, Butovsky O, Kaye JF, et al. Vaccination for Neuroprotection in the Mouse Optic Nerve: Implications for Optic Neuropathies. *J Neurosci*. 2001 Jan 1;21(1):136–42.
 182. Hazeldine J, Lord JM, Belli A. Traumatic Brain Injury and Peripheral Immune Suppression: Primer and Prospectus. *Front Neurol*. 2015 Nov 5;6.

183. Jesse S, Steinacker P, Cepek L, Arnim C V., Tumani H, Lehnert S, et al. Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease. *J Alzheimer's Dis.* 2009 Jul 1;17(3):541–51.
184. Posti JP, Takala RSK, Runtti H, Newcombe VF, Outtrim J, Katila AJ, et al. The Levels of Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 During the First Week After a Traumatic Brain Injury. *Neurosurgery.* 2016 Sep;79(3):456–64.
185. Mondello S, Kobeissy F, Vestri A, Hayes RL, Kochanek PM, Berger RP. Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury. *Sci Rep.* 2016 Jun 20;6(1):28203.
186. Yan EB, Satgunaseelan L, Paul E, Bye N, Nguyen P, Agyapomaa D, et al. Post-Traumatic Hypoxia Is Associated with Prolonged Cerebral Cytokine Production, Higher Serum Biomarker Levels, and Poor Outcome in Patients with Severe Traumatic Brain Injury. *J Neurotrauma.* 2014 Apr;31(7):618–29.
187. Ottens AK, Golden EC, Bustamante L, Hayes RL, Denslow ND, Wang KKW. Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry. *J Neurochem.* 2008 Mar;104(5):1404–14.
188. Cox AL, Coles AJ, Nortje J, Bradley PG, Chatfield DA, Thompson SJ, et al. An investigation of auto-reactivity after head injury. *J Neuroimmunol.* 2006 May;174(1–2):180–6.
189. Kalia V, Sarkar S, Ahmed R. CD8 T-Cell Memory Differentiation during Acute and Chronic Viral Infections. In 2010. p. 79–95.
190. Goverman J. Autoimmune T cell responses in the central nervous system. *Nat Rev Immunol.* 2009 Jun;9(6):393–407.
191. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. *Ann Neurol.* 2000 Jun;47(6):707–17.
192. Ransohoff RM, Kivisäkk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. *Nat Rev Immunol.* 2003 Jul;3(7):569–81.
193. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. *Front Cell Neurosci* [Internet]. 2013;7. Available from: <http://journal.frontiersin.org/article/10.3389/fncel.2013.00045/abstract>
194. Harry GJ. Microglia during development and aging. *Pharmacol Ther.* 2013 Sep;139(3):313–26.
195. Papa L, Brophy GM, Welch RD, Lewis LM, Braga CF, Tan CN, et al. Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury. *JAMA Neurol.* 2016 May 1;73(5):551.
196. Zoltewicz JS, Scharf D, Yang B, Chawla A, Newsom KJ, Fang L. Characterization of Antibodies that Detect Human GFAP after Traumatic Brain Injury. *Biomark Insights.* 2012 Jan 25;7:BMI.S9873.
197. Su E, Bell MJ, Kochanek PM, Wisniewski SR, Bayir H, Clark RSB, et al. Increased CSF Concentrations of Myelin Basic Protein After TBI in Infants and Children: Absence of Significant Effect of Therapeutic Hypothermia. *Neurocrit Care.* 2012 Dec 14;17(3):401–7.
198. Raper D, Louveau A, Kipnis J. How Do Meningeal Lymphatic Vessels Drain the CNS? *Trends Neurosci.* 2016 Sep;39(9):581–6.
199. Louveau A, Da Mesquita S, Kipnis J. Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease? *Neuron.* 2016 Sep;91(5):957–73.
200. Brait VH, Arumugam T V, Drummond GR, Sobey CG. Importance of T Lymphocytes in Brain Injury, Immunodeficiency, and Recovery after Cerebral Ischemia. *J Cereb Blood Flow Metab.* 2012 Apr 1;32(4):598–611.
201. Yang L, Kress BT, Weber HJ, Thiyagarajan M, Wang B, Deane R, et al. Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer. *J Transl Med.* 2013 Dec 1;11(1):107.
202. Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. *J Clin Invest.* 2013 Mar 1;123(3):1299–309.
203. Aspelund A, Antila S, Proulx ST, Karlsson TV, Karaman S, Detmar M, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *J Exp Med.* 2015 Jun 29;212(7):991–9.
204. Li M, Li F, Luo C, Shan Y, Zhang L, Qian Z, et al. Immediate Splenectomy Decreases Mortality and Improves Cognitive Function of Rats After Severe Traumatic Brain Injury. *J Trauma Inj Infect Crit Care.* 2011 Jul;71(1):141–7.
205. Chu W, Li M, Li F, Hu R, Chen Z, Lin J, et al. Immediate splenectomy down-regulates the MAPK–NF-κB signaling pathway in rat brain after severe traumatic brain injury. *J Trauma Acute Care Surg.* 2013 Jun;74(6):1446–53.
206. Teixeira PG, Karamanos E, Okoye OT, Talving P, Inaba K, Lam L, et al. Splenectomy in patients with traumatic brain injury. *J Trauma Acute Care Surg.* 2013 Oct;75(4):596–601.
207. Iwasaki A, Medzhitov R. Regulation of Adaptive Immunity by the Innate Immune System. *Science* (80-). 2010 Jan 15;327(5963):291–5.
208. Zhang J-M, An J. Cytokines, Inflammation, and Pain. *Int Anesthesiol Clin.* 2007;45(2):27–37.
209. Dinarello CA. Immunological and Inflammatory Functions of the Interleukin-1 Family. *Annu Rev Immunol.* 2009 Apr 1;27(1):519–50.
210. Garlanda C, Dinarello CA, Mantovani A. The Interleukin-1 Family: Back to the Future. *Immunity.* 2013 Dec;39(6):1003–18.
211. Pearson VL, Rothwell NJ, Toulmond S. Excitotoxic brain damage in the rat induces interleukin-1beta protein in microglia and astrocytes: correlation with the progression of cell death. *Glia.* 1999 Feb 15;25(4):311–23.
212. Dinarello CA. Blocking IL-1 in systemic inflammation. *J Exp Med.* 2005 May 2;201(9):1355–9.
213. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. *Am J Clin Nutr.* 2006 Feb 1;83(2):447S–455S.
214. Lu K-T, Wang Y-W, Wo Y-YP, Yang Y-L. Extracellular signal-regulated kinase-mediated IL-1-induced cortical neuron damage during traumatic brain injury. *Neurosci Lett.* 2005 Sep;386(1):40–5.
215. Grilli M, Memo M. Nuclear factor-κB/Rel proteins. *Biochem Pharmacol.* 1999 Jan;57(1):1–7.
216. Baeuerle PA, Baltimore D. NF-κB: Ten Years After. *Cell.* 1996 Oct;87(1):13–20.
217. Jander S, Stoll G. Differential induction of interleukin-12, interleukin-18, and interleukin-1β converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat. *J Neuroimmunol.* 1998 Nov;91(1–2):93–

- 9.
218. Losy J, Niezgoda A. IL-18 in patients with multiple sclerosis. *Acta Neurol Scand*. 2001 Sep;104(3):171–3.
219. Fassbender K, Mielke O, Bertsch T, Muehlhauser F, Hennerici M, Kurimoto M, et al. Interferon- γ -inducing factor (IL-18) and interferon- γ in inflammatory CNS diseases. *Neurology*. 1999 Sep 1;53(5):1104–1104.
220. Sims JE, Smith DE. The IL-1 family: regulators of immunity. *Nat Rev Immunol*. 2010 Feb 18;10(2):89–102.
221. Crespo ARTP, Da Rocha AB, Jotz GP, Schneider RF, Grivicich I, Pinheiro K, et al. Increased serum sFas and TNF α following isolated severe head injury in males. *Brain Inj*. 2007 Jan 3;21(4):441–7.
222. Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, et al. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. *Shock*. 2007 Dec;28(6):668–74.
223. Lorente L, Martín MM, González-Rivero AF, Ramos L, Argueso M, Cáceres JJ, et al. Serum soluble CD40 Ligand levels are associated with severity and mortality of brain trauma injury patients. *Thromb Res*. 2014 Oct;134(4):832–6.
224. Diamond ML, Ritter AC, Failla MD, Boles JA, Conley YP, Kochanek PM, et al. IL-1 β associations with posttraumatic epilepsy development: A genetics and biomarker cohort study. *Epilepsia*. 2014 Jul;55(7):1109–19.
225. Kohta M, Kohmura E, Yamashita T. Inhibition of TGF- β 1 promotes functional recovery after spinal cord injury. *Neurosci Res*. 2009 Dec;65(4):393–401.
226. Gyoneva S, Ransohoff RM. Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell–cell communication by chemokines. *Trends Pharmacol Sci [Internet]*. 2015 Jul;36(7):471–80. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165614715000759>
227. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M. Chemokines: Roles in leukocyte development, trafficking, and effector function. *J Allergy Clin Immunol*. 2003 Jun;111(6):1185–99.
228. Helmy A, Antoniadou CA, Guilfoyle MR, Carpenter KLH, Hutchinson PJ. Principal Component Analysis of the Cytokine and Chemokine Response to Human Traumatic Brain Injury. *PLoS One*. 2012 Jun 22;7(6):e39677.
229. Cartier O, Dubois-Dauphin M, Krause K-H. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. *Brain Res Rev*. 2005 Feb;48(1):16–42.
230. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. *Nat Rev Immunol*. 2011 Nov 10;11(11):762–74.
231. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. *Immunol Rev*. 2012 Sep;249(1):158–75.
232. Ting JP-Y, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, et al. The NLR Gene Family: A Standard Nomenclature. *Immunity*. 2008 Mar;28(3):285–7.
233. Liu H-D, Li W, Chen Z-R, Hu Y-C, Zhang D-D, Shen W, et al. Expression of the NLRP3 Inflammasome in Cerebral Cortex After Traumatic Brain Injury in a Rat Model. *Neurochem Res*. 2013 Oct 28;38(10):2072–83.
234. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid- β . *Nat Immunol*. 2008 Aug 11;9(8):857–65.
235. Borlongan C, Acosta S, de la Pena I, Tajiri N, Kaneko Y, Lozano D, et al. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. *Neuropsychiatr Dis Treat*. 2015 Jan;97.
236. Wang K, Cui D, Gao L. Traumatic brain injury a review of characteristics molecular basis and management. *Front Biosci*. 2016;21(5):4426.
237. Hinzman JM, Wilson JA, Mazzeo AT, Bullock MR, Hartings JA. Excitotoxicity and Metabolic Crisis Are Associated with Spreading Depolarizations in Severe Traumatic Brain Injury Patients. *J Neurotrauma*. 2016 Oct;33(19):1775–83.
238. Mbye LH, Singh IN, Sullivan PG, Springer JE, Hall ED. Attenuation of acute mitochondrial dysfunction after traumatic brain injury in mice by NIM811, a non-immunosuppressive cyclosporin A analog. *Exp Neurol*. 2008 Jan;209(1):243–53.
239. Cheng G, Kong R, Zhang L, Zhang J. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. *Br J Pharmacol*. 2012 Oct;167(4):699–719.
240. Burda JE, Bernstein AM, Sofroniew M V. Astrocyte roles in traumatic brain injury. *Exp Neurol*. 2016 Jan;275:305–15.
241. Shively SB, Horkayne-Szakaly I, Jones R V, Kelly JP, Armstrong RC, Perl DP. Characterisation of interface astroglial scarring in the human brain after blast exposure: a post-mortem case series. *Lancet Neurol*. 2016 Aug;15(9):944–53.
242. Yu S-W, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. *Proc Natl Acad Sci*. 2006 Nov 28;103(48):18314–9.
243. Bredesen D. Programmed Cell Death Mechanisms in Neurological Disease. *Curr Mol Med*. 2008 May 1;8(3):173–86.
244. Angeloni C, Prata C, Vieceli Dalla Sega F, Piperno R, Hrelia S. Traumatic Brain Injury and NADPH Oxidase: A Deep Relationship. *Oxid Med Cell Longev*. 2015;2015:1–10.
245. Bayly P V., Dikranian KT, Black EE, Young C, Qin Y-Q, Labruyere J, et al. Spatiotemporal evolution of apoptotic neurodegeneration following traumatic injury to the developing rat brain. *Brain Res*. 2006 Aug;1107(1):70–81.
246. Ohnishi T, Posner JB, Shapiro WR. Vasogenic Brain Edema Induced by Arachidonic Acid. *Neurosurgery [Internet]*. 1992 Apr;30(4):545–51. Available from: <http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006123-199204000-00012>
247. Olesen SP. Leakiness of rat brain microvessels to fluorescent probes following craniotomy. *Acta Physiol Scand*. 1987 May;130(1):63–8.
248. Mohanty S, Dey PK, Sharma HS, Singh S, Chansouria JPN, Olsson Y. Role of histamine in traumatic brain edema. *J Neurol Sci [Internet]*. 1989 Mar;90(1):87–97. Available from: <https://linkinghub.elsevier.com/retrieve/pii/0022510X89900488>
249. Butt AM, Jones HC. Effect of histamine and antagonists on electrical resistance across the blood-brain barrier in rat brain-surface microvessels. *Brain Res*. 1992 Jan;569(1):100–5.
250. Stokely ME, Orr EL. Acute Effects of Calvarial Damage on Dural Mast Cells, Pial Vascular Permeability, and

- Cerebral Cortical Histamine Levels in Rats and Mice. *J Neurotrauma*. 2008 Jan;25(1):52–61.
251. Haas HL, Sergeeva OA, Selbach O. Histamine in the Nervous System. *Physiol Rev*. 2008 Jul;88(3):1183–241.
252. ONODERA K, MIYAZAKI S. The roles of histamine H3 receptors in the behavioral disorders and neuropsychopharmacological aspects of its ligands in the brain. *Folia Pharmacol Jpn*. 1999;114(2):89–106.
253. Arrang J-M, Garbarg M, Schwartz J-C. Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors. *Neuroscience*. 1987 Oct;23(1):149–57.
254. Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, et al. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. *Brain Res*. 2008 Jun;1215:218–24.
255. Shimada R, Nakao K, Furutani R, Kibayashi K. A rat model of changes in dural mast cells and brain histamine receptor H3 expression following traumatic brain injury. *J Clin Neurosci*. 2012 Mar;19(3):447–51.
256. Schwartz LB. Mast cells and basophils. *Clin Allergy Immunol [Internet]*. 2002;16:3–42. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11577545>
257. Metz M, Grimbaldston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. *Immunol Rev*. 2007 Jun;217(1):304–28.
258. Galli SJ, Grimbaldston M, Tsai M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of innate and acquired immunity. *Nat Rev Immunol*. 2010 Jun;8(6):478–86.
259. Gilfillan AM, Austin SJ, Metcalfe DD. Mast cell biology: Introduction and overview. *Adv Exp Med Biol*. 2011;716:2–12.
260. Tete S, Tripodi D, Rosati M, Conti F, Maccauro G, Saggini A, et al. Role of mast cells in innate and adaptive immunity. *J Biol Regul Homeost Agents*. 26(2):193–201.
261. Saito H. Mast Cell Research. In 2014. p. 165–71.
262. Morita H, Saito H, Matsumoto K, Nakae S. Regulatory roles of mast cells in immune responses. *Semin Immunopathol*. 2016 Sep 6;38(5):623–9.
263. Brown MA, Hatfield JK. Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy? *Front Immunol*. 2012;3.
264. Conti P, Kempuraj D. Important role of mast cells in multiple sclerosis. *Mult Scler Relat Disord*. 2016 Jan;5:77–80.
265. Russi AE, Walker-Caulfield ME, Brown MA. Mast cell inflammasome activity in the meninges regulates EAE disease severity. *Clin Immunol [Internet]*. 2018 Apr;189:14–22. Available from: <http://dx.doi.org/10.1016/j.clim.2016.04.009>
266. Yehya M, Torbey MT. The Role of Mast Cells in Intracerebral Hemorrhage. *Neurocrit Care*. 2018 Jun 15;28(3):288–95.
267. Theoharides TC, Stewart JM, Panagiotidou S, Melamed I. Mast cells, brain inflammation and autism. *Eur J Pharmacol*. 2016 May;778:96–102.
268. Li W-W, Guo T-Z, Shi X, Sun Y, Wei T, Clark DJ, et al. Substance P spinal signaling induces glial activation and nociceptive sensitization after fracture. *Neuroscience [Internet]*. 2015 Dec;310(1):73–90. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0306452215008556>
269. Ryan JJ, Morales JK, Falanga YT, Fernando JFA, Macey MR. Mast Cell Regulation of the Immune Response. *World Allergy Organ J*. 2009;2(10):224–32.
270. Silver R, Curley JP. Mast cells on the mind: new insights and opportunities. *Trends Neurosci*. 2013 Sep;36(9):513–21.
271. Dong H, Zhang W, Zeng X, Hu G, Zhang H, He S, et al. Histamine Induces Upregulated Expression of Histamine Receptors and Increases Release of Inflammatory Mediators from Microglia. *Mol Neurobiol [Internet]*. 2014 Jun 22;49(3):1487–500. Available from: <http://link.springer.com/10.1007/s12035-014-8697-6>
272. Kritas SK, Caraffa A, Antinolfi P, Saggini A, Pantalone A, Rosati M, et al. Nerve Growth Factor Interactions with Mast Cells. *Int J Immunopathol Pharmacol*. 2014 Jan 1;27(1):15–9.
273. Zhang S, Dong H, Zhang X, Li N, Sun J, Qian Y. Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption. *Behav Brain Res [Internet]*. 2016 Feb;298:158–66. Available from: <http://dx.doi.org/10.1016/j.bbr.2015.11.003>
274. Skaper SD, Facci L, Giusti P. Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator. *Mol Neurobiol*. 2013 Oct 28;48(2):340–52.
275. Silverman A-J, Sutherland AK, Wilhelm M, Silver R. Mast Cells Migrate from Blood to Brain. *J Neurosci*. 2000 Jan 1;20(1):401–8.
276. Nelissen S, Lemmens E, Geurts N, Kramer P, Maurer M, Hendriks J, et al. The role of mast cells in neuroinflammation. *Acta Neuropathol*. 2013 May 13;125(5):637–50.
277. Theoharides TC, Alysandratos K-D, Angelidou A, Delivanis D-A, Sismanopoulos N, Zhang B, et al. Mast cells and inflammation. *Biochim Biophys Acta - Mol Basis Dis [Internet]*. 2012 Jan;1822(1):21–33. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S09255443910002929>
278. Kempuraj D, Khan MM, Thangavel R, Xiong Z, Yang E, Zaheer A. Glia maturation factor induces interleukin-33 release from astrocytes: Implications for neurodegenerative diseases. *J Neuroimmune Pharmacol*. 2013 Jun 10;8(3):643–50.
279. Sismanopoulos N, Delivanis D-A, Alysandratos K-D, Angelidou A, Therianou A, Kalogeromitros D, et al. Mast Cells in Allergic and Inflammatory Diseases. *Curr Pharm Des*. 2012 Apr 1;18(16):2261–77.
280. Kalesnikoff J, Galli SJ. New developments in mast cell biology. *Nat Immunol [Internet]*. 2008 Nov 21;9(11):1215–23. Available from: <http://www.nature.com/articles/ni.f.216>
281. Mekori YA, Metcalfe DD. Mast cells in innate immunity. *Immunol Rev*. 2000 Feb;173(1):131–40.
282. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. *Nat Rev Immunol*. 2005 Aug 20;5(8):629–40.
283. Brough D, Rothwell NJ, Allan SM. Interleukin-1 as a pharmacological target in acute brain injury. *Exp Physiol*. 2015 Dec 1;100(12):1488–94.
284. Allan SM, Rothwell NJ. Inflammation in central nervous system injury. *Philos Trans R Soc London Ser B Biol Sci*. 2003 Oct 29;358(1438):1669–77.
285. Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S, Boucher W, et al. IL-1 Induces

- Vesicular Secretion of IL-6 without Degranulation from Human Mast Cells. *J Immunol.* 2003 Nov 1;171(9):4830–6.
286. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: Partners in crime? *Immunology.* 2014 Mar;141(3):314–27.
287. Kim DY, Hong GU, Ro JY. Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L. *J Neuroinflammation.* 2011 Dec 16;8(1):25.
288. Zhang S, Zeng X, Yang H, Hu G, He S. Mast cell tryptase induces microglia activation via protease-activated receptor 2 signaling. *Cell Physiol Biochem.* 2012;29(5–6):931–40.
289. Enoksson M, Lyberg K, Möller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C. Mast Cells as Sensors of Cell Injury through IL-33 Recognition. *J Immunol.* 2011 Feb 15;186(4):2523–8.
290. Tore F, Tuncel N. Mast Cells: Target and Source of Neuropeptides. *Curr Pharm Des.* 2009 Oct 1;15(29):3433–45.
291. Skaper SD, Giusti P, Facci L. Microglia and mast cells: two tracks on the road to neuroinflammation. *FASEB J.* 2012 Aug 19;26(8):3103–17.
292. Skaper SD, Facci L. Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. *Philos Trans R Soc B Biol Sci.* 2012 Dec 5;367(1607):3312–25.
293. D. Skaper S. Mast Cell - Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications. *CNS Neurol Disord - Drug Targets.* 2016 Oct 7;15(9):1072–8.
294. Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H, et al. Neuroinflammation Induces Neurodegeneration. *J Neurol Neurosurg spine* [Internet]. 2016;1(1):1–15. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28127589> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5260818>
295. Li N, Zhang X, Dong H, Hu Y, Qian Y. Bidirectional relationship of mast cells-neurovascular unit communication in neuroinflammation and its involvement in POCD. *Behav Brain Res.* 2017 Mar;322:60–9.
296. Kempuraj D, Thangavel R, Fattal R, Pattani S, Yang E, Zaheer S, et al. Mast Cells Release Chemokine CCL2 in Response to Parkinsonian Toxin 1-Methyl-4-Phenyl-Pyridinium (MPP+). *Neurochem Res* [Internet]. 2016 May 8;41(5):1042–9. Available from: <http://link.springer.com/10.1007/s11064-015-1790-z>
297. Hösl L, Hösl E, Schneider U, Wiget W. Evidence for the existence of histamine H1- and H2-receptors on astrocytes of cultured rat central nervous system. *Neurosci Lett.* 1984 Aug;48(3):287–91.
298. Saito T, Bunnett NW. Protease-activated receptors: Regulation of neuronal function. *NeuroMolecular Med.* 2005;7(1–2):79–100.
299. Freeman JG, Ryan JJ, Shelburne CP, Bailey DP, Bouton LAA, Narasimhachari N, et al. Catecholamines in murine bone marrow derived mast cells. *J Neuroimmunol.* 2001 Oct;119(2):231–8.
300. Tanzola MB, Robbie-Ryan M, Gutekunst CA, Brown MA. Mast Cells Exert Effects Outside the Central Nervous System to Influence Experimental Allergic Encephalomyelitis Disease Course. *J Immunol.* 2003 Oct 15;171(8):4385–91.
301. Wilhelm M, Silver R, Silverman AJ. Central nervous system neurons acquire mast cell products via transgranulation. *Eur J Neurosci.* 2005 Nov;22(9):2238–48.
302. Héron A, Dubayle D. A focus on mast cells and pain. *J Neuroimmunol.* 2013 Nov;264(1–2):1–7.
303. Chikahisa S, Kodama T, Soya A, Sagawa Y, Ishimaru Y, Séi H, et al. Histamine from Brain Resident MAST Cells Promotes Wakefulness and Modulates Behavioral States. Mintz EM, editor. *PLoS One* [Internet]. 2013 Oct 18;8(10):e78434. Available from: <https://dx.plos.org/10.1371/journal.pone.0078434>
304. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. *Cell Mol Neurobiol.* 2000;20(2):131–47.
305. Theoharides TC, Rozniecki JJ, Sahagian G, Jacobson S, Kempuraj D, Conti P, et al. Impact of stress and mast cells on brain metastases. *J Neuroimmunol.* 2008 Dec;205(1–2):1–7.
306. Theoharides, Theoharis C. Corticotropin-releasing hormone and the blood-brain-barrier. *Front Biosci* [Internet]. 2007;12(1):1615. Available from: <https://fbscience.com/Landmark/articles/10.2741/2174>
307. Gu Y, Yang DK, Spinaz E, Kritas SK, Saggini A, Caraffa A, et al. Role of TNF in mast cell neuroinflammation and pain. *J Biol Regul Homeost Agents* [Internet]. 29(4):787–91. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26753638>
308. Niederhoffer N, Levy R, Sick E, Andre P, Coupin G, Lombard Y, et al. Amyloid β Peptides Trigger CD47-Dependent Mast Cell Secretory and Phagocytic Responses. *Int J Immunopathol Pharmacol* [Internet]. 2009 Apr 1;22(2):473–83. Available from: <http://journals.sagepub.com/doi/10.1177/039463200902200224>
309. Kvetnoř IM, Kvetnaia T V, Riadnova II, Fursov BB, Ernandes-Jago H, Blesa JR. [Expression of beta-amyloid and tau-protein in mastocytes in Alzheimer disease]. *Arkh Patol.* 65(1):36–9.
310. Kempuraj D, Thangavel R, Yang E, Pattani S, Zaheer S, Santillan DA, et al. Dopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α -Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators. *PLoS One.* 2015 Aug 14;10(8):e0135776.
311. Khan TK, Alkon DL. Peripheral biomarkers of Alzheimer’s disease. *J Alzheimer’s Dis.* 2015 Feb 6;44(3):729–44.
312. Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. *Acta Neuropathol.* 2010 Sep 20;120(3):277–86.
313. Villarán RF, Espinosa-Oliva AM, Sarmiento M, De Pablos RM, Argüelles S, Delgado-Cortés MJ, et al. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: Potential risk factor in Parkinson’s disease. *J Neurochem.* 2010 Sep;114(6):1687–700.
314. Machado A, Herrera AJ, Venero JL, Santiago M, De Pablos RM, Villarán RF, et al. Peripheral Inflammation Increases the Damage in Animal Models of Nigrostriatal Dopaminergic Neurodegeneration: Possible Implication in Parkinson’s Disease Incidence. *Parkinsons Dis.* 2011;2011:1–10.
315. Hernández-Romero MC, Delgado-Cortés MJMJ, Sarmiento M, de Pablos RM, Espinosa-Oliva AM, Argüelles S, et al. Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system. *Neurotoxicology.* 2012 Jun;33(3):347–60.
316. Träger U, Tabrizi SJ. Peripheral inflammation in neurodegeneration. *J Mol Med.* 2013 Jun 2;91(6):673–81.
317. Hoogland ICM, Houbolt C, van Westerlo DJ, van Gool WA, van de Beek D. Systemic inflammation and microglial activation: systematic review of animal experiments. *J Neuroinflammation.* 2015 Dec 6;12(1):114.

318. Takeda S, Sato N, Ikimura K, Nishino H, Rakugi H, Morishita R. Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model. *Neurobiol Aging* [Internet]. 2013 Aug;34(8):2064–70. Available from: <http://dx.doi.org/10.1016/j.neurobiolaging.2013.02.010>
319. Banks WA, Kastin AJ, Broadwell RD. Passage of Cytokines across the Blood-Brain Barrier. *Neuroimmunomodulation* [Internet]. 1995;2(4):241–8. Available from: <https://www.karger.com/Article/FullText/97202>
320. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. *Nat Rev Immunol*. 2007 Feb 15;7(2):161–7.
321. Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson P-J, Ericsson-Dahlstrand A. Pathway across the blood–brain barrier. *Nature*. 2001 Mar;410(6827):430–1.
322. Park H-S, Park M-J, Kwon M-S. Central Nervous System-Peripheral Immune System Dialogue in Neurological Disorders: Possible Application of Neuroimmunology in Urology. *Int Neurourol J*. 2016 May 26;20(Suppl 1):S8–14.
323. Tracey KJ. Reflex control of immunity. *Nat Rev Immunol*. 2009 Jun;9(6):418–28.
324. Kortekaas R, Leenders KL, van Oostrom JCH, Vaalburg W, Bart J, Willemsen ATM, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. *Ann Neurol*. 2005 Feb;57(2):176–9.
325. Karagkouni A, Alevizos M, Theoharides TC. Effect of stress on brain inflammation and multiple sclerosis. *Autoimmun Rev* [Internet]. 2013 Aug;12(10):947–53. Available from: <http://dx.doi.org/10.1016/j.autrev.2013.02.006>
326. Goldeck D, M. Witkowski J, Fülöp T, Pawelec G. Peripheral Immune Signatures in Alzheimer Disease. *Curr Alzheimer Res* [Internet]. 2016 May 11;13(7):739–49. Available from: <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1567-2050&volume=13&issue=7&spage=739>
327. Ransohoff RM, Brown MA. Innate immunity in the central nervous system Find the latest version : Review series Innate immunity in the central nervous system. *J Clin Invest* [Internet]. 2012;122(4):1164–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22466658>
328. Kempuraj D, Devi RS, Madhappan B, Conti P, Nazer MY, Christodoulou S, et al. T Lymphocyte Subsets and Immunoglobulins in Intracranial Tumor Patients before and after Treatment and Based on Histological Type of Tumors. *Int J Immunopathol Pharmacol*. 2004 Jan 23;17(1):57–64.
329. Kempuraj D, Thangavel R, Selvakumar GP, Zaheer S, Ahmed ME, Raikwar SP, et al. Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration. *Front Cell Neurosci*. 2017 Jul 24;11.
330. Lawson LJ, Perry VH, Gordon S. Turnover of resident microglia in the normal adult mouse brain. *Neuroscience* [Internet]. 1992 May;48(2):405–15. Available from: <https://linkinghub.elsevier.com/retrieve/pii/0306452292905002>
331. Hugh Perry V. A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. *J Neuroimmunol* [Internet]. 1998 Oct;90(2):113–21. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165572898001453>
332. Perry VH, Nicoll JAR, Holmes C. Microglia in neurodegenerative disease. *Nat Rev Neurol* [Internet]. 2010 Apr 16;6(4):193–201. Available from: <http://www.nature.com/articles/nrneuro.2010.17>
333. Daneman R. The blood-brain barrier in health and disease. *Ann Neurol* [Internet]. 2012 Nov;72(5):648–72. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/ana.23648>
334. Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A. Physiology of Microglia. *Physiol Rev* [Internet]. 2011 Apr;91(2):461–553. Available from: <https://www.physiology.org/doi/10.1152/physrev.00011.2010>
335. Kingwell K. Microglia in early disease stages. *Nat Rev Neurol* [Internet]. 2012 Sep 14;8(9):475–475. Available from: <http://www.nature.com/articles/nrneuro.2012.172>
336. Graeber MB. Changing Face of Microglia. *Science* (80-) [Internet]. 2010 Nov 5;330(6005):783–8. Available from: <https://www.science.org/doi/10.1126/science.1190929>
337. Tremblay M-É, Lowery RL, Majewska AK. Microglial Interactions with Synapses Are Modulated by Visual Experience. Dalva M, editor. *PLoS Biol* [Internet]. 2010 Nov 2;8(11):e1000527. Available from: <https://dx.plos.org/10.1371/journal.pbio.1000527>
338. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. Synaptic Pruning by Microglia Is Necessary for Normal Brain Development. *Science* (80-) [Internet]. 2011 Sep 9;333(6048):1456–8. Available from: <https://www.science.org/doi/10.1126/science.1202529>
339. Rezaie P, Male D. MESOGLIA & MICROGLIA – A Historical Review of the Concept of Mononuclear Phagocytes Within the Central Nervous System. *J Hist Neurosci* [Internet]. 2002 Nov 9;11(4):325–74. Available from: <http://www.tandfonline.com/doi/abs/10.1076/jhin.11.4.325.8531>
340. Perry VH, Hume DA, Gordon S. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. *Neuroscience* [Internet]. 1985 Jun;15(2):313–26. Available from: <https://linkinghub.elsevier.com/retrieve/pii/0306452285902155>
341. Chan WY, Kohsaka S, Rezaie P. The origin and cell lineage of microglia—New concepts. *Brain Res Rev* [Internet]. 2007 Feb;53(2):344–54. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165017306001184>
342. Ransohoff RM, Perry VH. Microglial Physiology: Unique Stimuli, Specialized Responses. *Annu Rev Immunol* [Internet]. 2009 Apr 1;27(1):119–45. Available from: <https://www.annualreviews.org/doi/10.1146/annurev.immunol.021908.132528>
343. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? *Trends Immunol* [Internet]. 2007 Jan;28(1):12–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1471490606003267>
344. Boche D, Perry VH, Nicoll JAR. Review: Activation patterns of microglia and their identification in the human brain. *Neuropathol Appl Neurobiol* [Internet]. 2013 Feb;39(1):3–18. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/nan.12011>
345. Madathil SK, Wilfred BS, Urankar SE, Yang W, Leung LY, Gilsdorf JS, et al. Early Microglial Activation Following Closed-Head Concussive Injury Is Dominated by Pro-Inflammatory M-1 Type. *Front Neurol* [Internet]. 2018 Nov 15;9. Available from: <https://www.frontiersin.org/article/10.3389/fneur.2018.00964/full>

346. Donat CK, Scott G, Gentleman SM, Sastre M. Microglial Activation in Traumatic Brain Injury. *Front Aging Neurosci* [Internet]. 2017 Jun 28;9. Available from: <http://journal.frontiersin.org/article/10.3389/fnagi.2017.00208/full>
347. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. *J Neurol Neurosurg Psychiatry* [Internet]. 1994 Apr 1;57(4):419–25. Available from: <https://jnnp.bmj.com/lookup/doi/10.1136/jnnp.57.4.419>
348. Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: A systematic review and meta-analysis. *Mov Disord* [Internet]. 2013 Aug;28(9):1222–9. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/mds.25458>
349. Chiu C-C, Liao Y-E, Yang L-Y, Wang J-Y, Tweedie D, Karnati HK, et al. Neuroinflammation in animal models of traumatic brain injury. *J Neurosci Methods* [Internet]. 2016 Oct;272:38–49. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165027016301479>
350. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen KM, et al. Inflammation after trauma: Microglial activation and traumatic brain injury. *Ann Neurol* [Internet]. 2011 Sep;70(3):374–83. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/ana.22455>
351. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. *Brain* [Internet]. 2013 Jan;136(1):28–42. Available from: <https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/aws322>
352. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. *Br J Anaesth* [Internet]. 2007 Jul;99(1):4–9. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0007091217347840>
353. Faden AI, Wu J, Stoica BA, Loane DJ. Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury. *Br J Pharmacol* [Internet]. 2016 Feb;173(4):681–91. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/bph.13179>
354. Solito E, Sastre M. Microglia Function in Alzheimer's Disease. *Front Pharmacol* [Internet]. 2012;3. Available from: <http://journal.frontiersin.org/article/10.3389/fphar.2012.00014/abstract>
355. Zhang Z, Zhang Z-Y, Wu Y, Schluesener HJ. Immunolocalization of Toll-Like Receptors 2 and 4 as well as Their Endogenous Ligand, Heat Shock Protein 70, in Rat Traumatic Brain Injury. *Neuroimmunomodulation* [Internet]. 2012;19(1):10–9. Available from: <https://www.karger.com/Article/FullText/326771>
356. Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K. L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: the 'collusion' hypothesis for increased extracellular L-glutamate concentration in neuroinflammation. *J Neuroinflammation* [Internet]. 2012 Dec 23;9(1):275. Available from: <https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-275>
357. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. *Neurotherapeutics* [Internet]. 2010 Jan;7(1):22–30. Available from: <http://link.springer.com/10.1016/j.nurt.2009.10.016>
358. Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, et al. Microglial and macrophage polarization—new prospects for brain repair. *Nat Rev Neurol* [Internet]. 2015 Jan 11;11(1):56–64. Available from: <http://www.nature.com/articles/nrneurol.2014.207>
359. Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang L, Means TK, et al. The microglial sensome revealed by direct RNA sequencing. *Nat Neurosci* [Internet]. 2013 Dec 27;16(12):1896–905. Available from: <http://www.nature.com/articles/nn.3554>
360. Xu L, Nguyen J V., Lehar M, Menon A, Rha E, Arena J, et al. Repetitive mild traumatic brain injury with impact acceleration in the mouse: Multifocal axonopathy, neuroinflammation, and neurodegeneration in the visual system. *Exp Neurol* [Internet]. 2016 Jan;275:436–49. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0014488614003641>
361. Coimbra R, Hoyt DB, Potenza BM, Fortlage D, Hollingsworth-Fridlund P. Does Sexual Dimorphism Influence Outcome of Traumatic Brain Injury Patients? The Answer Is No! *J Trauma Inj Infect Crit Care* [Internet]. 2003 Apr;54(4):689–700. Available from: <http://journals.lww.com/00005373-200304000-00008>
362. Phelan HA, Shafi S, Parks J, Maxson RT, Ahmad N, Murphy JT, et al. Use of a Pediatric Cohort to Examine Gender and Sex Hormone Influences on Outcome After Trauma. *J Trauma Inj Infect Crit Care* [Internet]. 2007 Nov;63(5):1127–31. Available from: <https://journals.lww.com/00005373-200711000-00025>
363. Berry C, Ley EJ, Tillou A, Cryer G, Margulies DR, Salim A. The Effect of Gender on Patients With Moderate to Severe Head Injuries. *J Trauma Inj Infect Crit Care* [Internet]. 2009 Nov;67(5):950–3. Available from: <https://journals.lww.com/00005373-200911000-00009>
364. Ley EJ, Short SS, Liou DZ, Singer MB, Mirocha J, Melo N, et al. Gender impacts mortality after traumatic brain injury in teenagers. *J Trauma Acute Care Surg* [Internet]. 2013 Oct;75(4):682–6. Available from: <https://journals.lww.com/01586154-201310000-00020>
365. Caplan HW, Cox CS, Bedi SS. Do microglia play a role in sex differences in TBI? *J Neurosci Res* [Internet]. 2017 Jan 2;95(1–2):509–17. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jnr.23854>
366. Lenz KM, McCarthy MM. A Starring Role for Microglia in Brain Sex Differences. *Neurosci* [Internet]. 2015 Jun 28;21(3):306–21. Available from: <http://journals.sagepub.com/doi/10.1177/1073858414536468>
367. Menzies FM, Henriquez FL, Alexander J, Roberts CW. Selective inhibition and augmentation of alternative macrophage activation by progesterone. *Immunology* [Internet]. 2011 Nov;134(3):281–91. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2567.2011.03488.x>
368. Chio C-C, Lin M-T, Chang C-P. Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury. *Curr Med Chem* [Internet]. 2015 Jan 20;22(6):759–70. Available from: <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=0929-8673&volume=22&issue=6&spage=759>
369. Koh TJ, DiPietro LA. Inflammation and wound healing: the role of the macrophage. *Expert Rev Mol Med* [Internet]. 2011 Jul 11;13:e23. Available from: https://www.cambridge.org/core/product/identifier/S146239941001943/type/journal_article
370. Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. *Br J Pharmacol* [Internet]. 2013

- May;169(2):337–52. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/bph.12139>
371. Kim JH, Jenrow KA, Brown SL. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. *Radiat Oncol J* [Internet]. 2014;32(3):103. Available from: <http://e-roj.org/journal/view.php?doi=10.3857/roj.2014.32.3.103>
372. Coughlin JM, Wang Y, Minn I, Bienko N, Ambinder EB, Xu X, et al. Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. *JAMA Neurol* [Internet]. 2017 Jan 1;74(1):67. Available from: <http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2016.3764>
373. Russo M V., McGavern DB. Inflammatory neuroprotection following traumatic brain injury. *Science* (80-) [Internet]. 2016 Aug 19;353(6301):783–5. Available from: <https://www.science.org/doi/10.1126/science.aaf6260>
374. Corps KN, Roth TL, McGavern DB. Inflammation and Neuroprotection in Traumatic Brain Injury. *JAMA Neurol* [Internet]. 2015 Mar 1;72(3):355. Available from: <http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2014.3558>
375. Colton CA, Wilcock DM. Assessing Activation States in Microglia. *CNS Neurol Disord - Drug Targets* [Internet]. 2010 Apr 1;9(2):174–91. Available from: <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5273&volume=9&issue=2&spage=174>
376. Bell-Temin H, Culver-Cochran A, Chaput D, Carlson C, Kuehl M, Burkhardt B, et al. Novel Molecular Insights into Classical and Alternative Activation States of Microglia as Revealed by Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC)-based Proteomics*. *Mol Cell Proteomics* [Internet]. 2015 Dec;14(12):3173–84. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1535947620328309>
377. Xu H, Wang Z, Li J, Wu H, Peng Y, Fan L, et al. The Polarization States of Microglia in TBI: A New Paradigm for Pharmacological Intervention. *Neural Plast* [Internet]. 2017;2017:1–11. Available from: <https://www.hindawi.com/journals/np/2017/5405104/>
378. Izzy S, Liu Q, Fang Z, Lule S, Wu L, Chung JY, et al. Time-Dependent Changes in Microglia Transcriptional Networks Following Traumatic Brain Injury. *Front Cell Neurosci* [Internet]. 2019 Aug 8;13. Available from: <https://www.frontiersin.org/article/10.3389/fncel.2019.00307/full>
379. Ransohoff RM, Khoury J El. Microglia in Health and Disease. *Cold Spring Harb Perspect Biol* [Internet]. 2016 Jan;8(1):a020560. Available from: <http://cshperspectives.cshlp.org/lookup/doi/10.1101/cshperspect.a020560>
380. Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. *Nat Neurosci* [Internet]. 2018 Oct 26;21(10):1359–69. Available from: <http://www.nature.com/articles/s41593-018-0242-x>
381. Jassam YN, Izzy S, Whalen M, McGavern DB, El Khoury J. Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift. *Neuron* [Internet]. 2017 Sep;95(6):1246–65. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0896627317306128>
382. Liu Y-W, Li S, Dai S-S. Neutrophils in traumatic brain injury (TBI): friend or foe? *J Neuroinflammation* [Internet]. 2018 Dec 17;15(1):146. Available from: <https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-018-1173-x>
383. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17. *J Biol Chem* [Internet]. 2003 Jan;278(3):1910–4. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0021925819311184>
384. Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, Finnson KW, et al. The TGF- β co-receptor, CD109, promotes internalization and degradation of TGF- β receptors. *Biochim Biophys Acta - Mol Cell Res* [Internet]. 2011 May;1813(5):742–53. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S016748891100036X>
385. Szmydynger-Chodobska J, Shan R, Thomasian N, Chodobski A. The Involvement of Pial Microvessels in Leukocyte Invasion after Mild Traumatic Brain Injury. *Kobeissy FH, editor. PLoS One* [Internet]. 2016 Dec 28;11(12):e0167677. Available from: <https://dx.plos.org/10.1371/journal.pone.0167677>
386. Arneson D, Zhang G, Ying Z, Zhuang Y, Byun HR, Ahn IS, et al. Single cell molecular alterations reveal target cells and pathways of concussive brain injury. *Nat Commun* [Internet]. 2018 Dec 25;9(1):3894. Available from: <http://www.nature.com/articles/s41467-018-06222-0>
387. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 Macrophages and the Th1/Th2 Paradigm. *J Immunol* [Internet]. 2000 Jun 15;164(12):6166–73. Available from: <http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.164.12.6166>
388. Jing J, Yang I V., Hui L, Patel JA, Evans CM, Prikeris R, et al. Role of Macrophage Receptor with Collagenous Structure in Innate Immune Tolerance. *J Immunol* [Internet]. 2013 Jun 15;190(12):6360–7. Available from: <http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1202942>
389. Hammad A, Westacott L, Zaben M. The role of the complement system in traumatic brain injury: a review. *J Neuroinflammation* [Internet]. 2018 Dec 22;15(1):24. Available from: <https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-018-1066-z>
390. Yager PH, You Z, Qin T, Kim H-H, Takahashi K, Ezekowitz AB, et al. Mannose Binding Lectin Gene Deficiency Increases Susceptibility to Traumatic Brain Injury in Mice. *J Cereb Blood Flow Metab* [Internet]. 2008 May 9;28(5):1030–9. Available from: <http://journals.sagepub.com/doi/10.1038/sj.jcbfm.9600605>
391. Alawieh A, Langley EF, Weber S, Adkins D, Tomlinson S. Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury. *J Neurosci* [Internet]. 2018 Mar 7;38(10):2519–32. Available from: <https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.2197-17.2018>
392. Szmydynger-Chodobska J, Strazielle N, Zink BJ, Ghersi-Egea J-F, Chodobski A. The Role of the Choroid Plexus in Neutrophil Invasion after Traumatic Brain Injury. *J Cereb Blood Flow Metab* [Internet]. 2009 Sep 27;29(9):1503–16. Available from: <http://journals.sagepub.com/doi/10.1038/jcbfm.2009.71>
393. Atkins CM, Oliva AA, Alonso OF, Pearse DD, Bramlett HM, Dietrich WD. Modulation of the cAMP signaling pathway after traumatic brain injury. *Exp Neurol* [Internet]. 2007 Nov;208(1):145–58. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S001448860700324X>
394. Block F, Tondar A, Schmidt W, Schwarz M. Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats. *Neuroreport* [Internet]. 1997 Dec;8(17):3829–32. Available from: <http://journals.lww.com/00001756-199712010-00033>

395. Nikulina E, Tidwell JL, Dai HN, Bregman BS, Filbin MT. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. *Proc Natl Acad Sci* [Internet]. 2004 Jun 8;101(23):8786–90. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.0402595101>
396. Nishihara T, Ochi M, Sugimoto K, Takahashi H, Yano H, Kumon Y, et al. Subcutaneous injection containing IL-3 and GM-CSF ameliorates stab wound-induced brain injury in rats. *Exp Neurol* [Internet]. 2011 Jun;229(2):507–16. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0014488611001208>
397. Ding JY, Kreipke CW, Speirs SL, Schafer P, Schafer S, Rafols JA. Hypoxia-inducible factor-1 α signaling in aquaporin upregulation after traumatic brain injury. *Neurosci Lett* [Internet]. 2009 Mar;453(1):68–72. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0304394009001517>
398. Huang R, Cheng H, Zhao X, Dai W, Zhuang Z, Wu Y, et al. Preliminary study on the effect of trauma-induced secondary cellular hypoxia in brain injury. *Neurosci Lett* [Internet]. 2010 Mar;473(1):22–7. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0304394010001692>
399. Yan J, Zhou B, Taheri S, Shi H. Differential Effects of HIF-1 Inhibition by YC-1 on the Overall Outcome and Blood-Brain Barrier Damage in a Rat Model of Ischemic Stroke. Kleinschnitz C, editor. *PLoS One* [Internet]. 2011 Nov 16;6(11):e27798. Available from: <https://dx.plos.org/10.1371/journal.pone.0027798>
400. Higashida T, Peng C, Li J, Dornbos D, Teng K, Li X, et al. Hypoxia-Inducible Factor-1 α ; Contributes to Brain Edema after Stroke by Regulating Aquaporins and Glycerol Distribution in Brain. *Curr Neurovasc Res* [Internet]. 2011 Feb 1;8(1):44–51. Available from: <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1567-2026&volume=8&issue=1&spage=44>
401. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. *Proc Natl Acad Sci* [Internet]. 2000 Aug 1;97(16):9082–7. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.97.16.9082>
402. Habib P, Slowik A, Zendedel A, Johann S, Dang J, Beyer C. Regulation of Hypoxia-Induced Inflammatory Responses and M1-M2 Phenotype Switch of Primary Rat Microglia by Sex Steroids. *J Mol Neurosci* [Internet]. 2014 Feb 27;52(2):277–85. Available from: <http://link.springer.com/10.1007/s12031-013-0137-y>
403. Aryanpour R, Pasbakhsh P, Zibara K, Namjoo Z, Beigi Boroujeni F, Shahbeigi S, et al. Progesterone therapy induces an M1 to M2 switch in microglia phenotype and suppresses NLRP3 inflammasome in a cuprizone-induced demyelination mouse model. *Int Immunopharmacol* [Internet]. 2017 Oct;51:131–9. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1567576917303053>
404. Yao X, Liu S, Ding W, Yue P, Jiang Q, Zhao M, et al. TLR4 signal ablation attenuated neurological deficits by regulating microglial M1/M2 phenotype after traumatic brain injury in mice. *J Neuroimmunol* [Internet]. 2017 Sep;310:38–45. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165572817300401>
405. McPherson CA, Merrick BA, Harry GJ. In Vivo Molecular Markers for Pro-inflammatory Cytokine M1 Stage and Resident Microglia in Trimethyltin-Induced Hippocampal Injury. *Neurotox Res* [Internet]. 2014 Jan 4;25(1):45–56. Available from: <http://link.springer.com/10.1007/s12640-013-9422-3>
406. Norden DM, Trojanowski PJ, Villanueva E, Navarro E, Godbout JP. Sequential activation of microglia and astrocyte cytokine expression precedes increased iba-1 or GFAP immunoreactivity following systemic immune challenge. *Glia* [Internet]. 2016 Feb;64(2):300–16. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/glia.22930>
407. Schumann J, Alexandrovich GA, Biegona A, Yaka R. Inhibition of NR2B Phosphorylation Restores Alterations in NMDA Receptor Expression and Improves Functional Recovery following Traumatic Brain Injury in Mice. *J Neurotrauma* [Internet]. 2008 Aug;25(8):945–57. Available from: <http://www.liebertpub.com/doi/10.1089/neu.2008.0521>
408. Chen T, Dai S-H, Jiang Z-Q, Luo P, Jiang X-F, Fei Z, et al. The AMPAR Antagonist Perampanel Attenuates Traumatic Brain Injury Through Anti-Oxidative and Anti-Inflammatory Activity. *Cell Mol Neurobiol* [Internet]. 2017 Jan 16;37(1):43–52. Available from: <http://link.springer.com/10.1007/s10571-016-0341-8>
409. Laffer B, Bauer D, Wasmuth S, Busch M, Jalilvand TV, Thanos S, et al. Loss of IL-10 Promotes Differentiation of Microglia to a M1 Phenotype. *Front Cell Neurosci* [Internet]. 2019 Oct 9;13. Available from: <https://www.frontiersin.org/article/10.3389/fncel.2019.00430/full>
410. Savage CD, Lopez-Castejon G, Denes A, Brough D. NLRP3-Inflammasome Activating DAMPs Stimulate an Inflammatory Response in Glia in the Absence of Priming Which Contributes to Brain Inflammation after Injury. *Front Immunol* [Internet]. 2012;3. Available from: <http://journal.frontiersin.org/article/10.3389/fimmu.2012.00288/abstract>
411. Neher JJ, Neniskyte U, Brown GC. Primary Phagocytosis of Neurons by Inflamed Microglia: Potential Roles in Neurodegeneration. *Front Pharmacol* [Internet]. 2012;3. Available from: <http://journal.frontiersin.org/article/10.3389/fphar.2012.00027/abstract>
412. Weissberg I, Veksler R, Kamintsky L, Saar-Ashkenazy R, Milikovsky DZ, Shelef I, et al. Imaging Blood-Brain Barrier Dysfunction in Football Players. *JAMA Neurol* [Internet]. 2014 Nov 1;71(11):1453. Available from: <http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2014.2682>
413. Afonso P V., Ozden S, Cumont M-C, Seilhean D, Cartier L, Rezaie P, et al. Alteration of Blood-Brain Barrier Integrity by Retroviral Infection. Luban J, editor. *PLoS Pathog* [Internet]. 2008 Nov 14;4(11):e1000205. Available from: <https://dx.plos.org/10.1371/journal.ppat.1000205>
414. Chodobski A, Zink BJ, Szymdynger-Chodobska J. Blood-Brain Barrier Pathophysiology in Traumatic Brain Injury. *Transl Stroke Res* [Internet]. 2011 Dec 11;2(4):492–516. Available from: <http://link.springer.com/10.1007/s12975-011-0125-x>
415. Başkaya MK, Muralikrishna Rao A, Doğan A, Donaldson D, Dempsey RJ. The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats. *Neurosci Lett* [Internet]. 1997 Apr;226(1):33–6. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0304394097002395>
416. Ren Z, Iliff JJ, Yang L, Yang J, Chen X, Chen MJ, et al. ‘Hit & Run’ Model of Closed-Skull Traumatic Brain Injury (TBI) Reveals Complex Patterns of Post-Traumatic AQP4 Dysregulation. *J Cereb Blood Flow Metab* [Internet]. 2013 Jun 27;33(6):834–45. Available from: <http://journals.sagepub.com/doi/10.1038/jcbfm.2013.30>
417. Shetty AK, Mishra V, Kodali M, Hattiangady B. Blood brain barrier dysfunction and delayed neurological deficits in mild traumatic brain injury induced by blast shock waves. *Front Cell Neurosci* [Internet]. 2014 Aug 13;8.

- Available from: <http://journal.frontiersin.org/article/10.3389/fncel.2014.00232/abstract>
418. Yang SH, Gustafson J, Gangidine M, Stepien D, Schuster R, Pritts TA, et al. A murine model of mild traumatic brain injury exhibiting cognitive and motor deficits. *J Surg Res* [Internet]. 2013 Oct;184(2):981–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S002248041300293X>
 419. Kane MJ, Angoa-Pérez M, Briggs DI, Viano DC, Kreipke CW, Kuhn DM. A mouse model of human repetitive mild traumatic brain injury. *J Neurosci Methods* [Internet]. 2012 Jan;203(1):41–9. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165027011005255>
 420. Zohar O, Schreiber S, Getslev V, Schwartz J. P, Mullins P. G, Pick C. G. Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice. *Neuroscience* [Internet]. 2003 Jun;118(4):949–55. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0306452203000484>
 421. O'Connor CA, Cernak I, Vink R. The temporal profile of edema formation differs between male and female rats following diffuse traumatic brain injury. In: *Brain Edema XIII* [Internet]. Vienna: Springer-Verlag; p. 121–4. Available from: http://link.springer.com/10.1007/3-211-30714-1_27
 422. Bye N, Habgood MD, Callaway JK, Malakooti N, Potter A, Kossmann T, et al. Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. *Exp Neurol* [Internet]. 2007 Mar;204(1):220–33. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17188268>
 423. Stahel PF, Shohami E, Younis FM, Kariya K, Otto VI, Lenzlinger PM, et al. Experimental Closed Head Injury: Analysis of Neurological Outcome, Blood–Brain Barrier Dysfunction, Intracranial Neutrophil Infiltration, and Neuronal Cell Death in Mice Deficient in Genes for Pro-Inflammatory Cytokines. *J Cereb Blood Flow Metab* [Internet]. 2000 Feb;20(2):369–80. Available from: <http://journals.sagepub.com/doi/10.1097/00004647-200002000-00019>
 424. Hsieh CL, Kim CC, Ryba BE, Niemi EC, Bando JK, Locksley RM, et al. Traumatic brain injury induces macrophage subsets in the brain. *Eur J Immunol* [Internet]. 2013 Aug;43(8):2010–22. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/eji.201243084>
 425. Hsieh CL, Niemi EC, Wang SH, Lee CC, Bingham D, Zhang J, et al. CCR2 Deficiency Impairs Macrophage Infiltration and Improves Cognitive Function after Traumatic Brain Injury. *J Neurotrauma* [Internet]. 2014 Oct 15;31(20):1677–88. Available from: <http://www.liebertpub.com/doi/10.1089/neu.2013.3252>
 426. Hausmann R, Kaiser A, Lang C, Bohnert M, Betz P. A quantitative immunohistochemical study on the time-dependent course of acute inflammatory cellular response to human brain injury. *Int J Legal Med* [Internet]. 1999 Jun 18;112(4):227–32. Available from: <http://link.springer.com/10.1007/s004140050241>
 427. Eyolfson E, Khan A, Mychasiuk R, Lohman AW. Microglia dynamics in adolescent traumatic brain injury. *J Neuroinflammation* [Internet]. 2020 Dec 29;17(1):326. Available from: <https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-020-01994-z>
 428. Csuka E, Hans VHJ, Ammann E, Trentz O, Kossmann T, Morganti-Kossmann MC. Cell activation and inflammatory response following traumatic axonal injury in the rat. *Neuroreport* [Internet]. 2000 Aug;11(11):2587–90. Available from: <http://journals.lww.com/00001756-200008030-00047>
 429. Popovich PG. Immunological regulation of neuronal degeneration and regeneration in the injured spinal cord. In 2000. p. 43–58. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0079612300280060>
 430. Gao H-M, Liu B, Zhang W, Hong J-S. Novel anti-inflammatory therapy for Parkinson's disease. *Trends Pharmacol Sci* [Internet]. 2003 Aug;24(8):395–401. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165614703001767>
 431. Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hövelmeyer N, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. *Nat Med* [Internet]. 2005 Feb 1;11(2):146–52. Available from: <http://www.nature.com/articles/nm1177>
 432. Block ML, Hong J-S. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. *Prog Neurobiol* [Internet]. 2005 Jun;76(2):77–98. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0301008205000675>
 433. Herrera AJ, Tomás-Camardiel M, Venero JL, Cano J, Machado A. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. *J Neural Transm* [Internet]. 2005 Jan 19;112(1):111–9. Available from: <http://link.springer.com/10.1007/s00702-004-0121-3>
 434. Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OAR, Malolepszy J, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. *Nature* [Internet]. 2001 Sep;413(6854):420–5. Available from: <http://www.nature.com/articles/35096564>
 435. Akdis CA, Simons FER. Histamine receptors are hot in immunopharmacology. *Eur J Pharmacol* [Internet]. 2006 Mar;533(1–3):69–76. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0014299905013555>
 436. Repka-Ramirez MS, Baraniuk JN. Histamine in health and disease. *Clin Allergy Immunol* [Internet]. 2002;17:1–25. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12113214>
 437. Tiligada E, Zampeli E, Sander K, Stark H. Histamine H3 and H4 receptors as novel drug targets. *Expert Opin Investig Drugs* [Internet]. 2009 Oct 17;18(10):1519–31. Available from: <http://www.tandfonline.com/doi/full/10.1517/14728220903188438>
 438. Huang J-F, Thurmond RL. The new biology of histamine receptors. *Curr Allergy Asthma Rep* [Internet]. 2008 Jan 30;8(1):21–7. Available from: <http://link.springer.com/10.1007/s11882-008-0005-y>
 439. Minghetti L. Role of inflammation in neurodegenerative diseases. *Curr Opin Neurol* [Internet]. 2005 Jun;18(3):315–21. Available from: <https://journals.lww.com/00019052-200506000-00019>
 440. Streit WJ, Conde JR, Fendrick SE, Flanary BE, Mariani CL. Role of microglia in the central nervous system's immune response. *Neurol Res* [Internet]. 2005 Oct 1;27(7):685–91. Available from: <https://www.tandfonline.com/doi/full/10.1179/016164105X49463a>
 441. Tweedie D, Sambamurti K, Greig N. TNF- α ; Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. *Curr Alzheimer Res* [Internet]. 2007 Sep 1;4(4):378–85. Available from: <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1567-2050&volume=4&issue=4&spage=378>
 442. Gurol DL, Nelson TE. Physiological and pathological roles of interleukin-6 in the central nervous system. *Mol*

- Neurobiol [Internet]. 1997 Dec;15(3):307–39. Available from: <http://link.springer.com/10.1007/BF02740665>
443. Linker RA, Lühder F, Kallen K-J, Lee D-H, Engelhardt B, Rose-John S, et al. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. *J Neuroimmunol* [Internet]. 2008 Dec;205(1–2):64–72. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165572808003998>
444. Quintana A, Müller M, Frausto RF, Ramos R, Getts DR, Sanz E, et al. Site-Specific Production of IL-6 in the Central Nervous System Retargets and Enhances the Inflammatory Response in Experimental Autoimmune Encephalomyelitis. *J Immunol* [Internet]. 2009 Aug 1;183(3):2079–88. Available from: <http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.0900242>
445. Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT, et al. IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. *J Neuroinflammation* [Internet]. 2011 Dec 19;8(1):52. Available from: <https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-52>
446. Gadiant RA, Otten UH. Interleukin-6 (IL-6)—A molecule with both beneficial and destructive potentials. *Prog Neurobiol* [Internet]. 1997 Aug;52(5):379–90. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S030100829700021X>
447. Ikarashi Y, Yuzurihara M. Experimental anxiety induced by histaminergics in mast cell-deficient and congenitally normal mice. *Pharmacol Biochem Behav* [Internet]. 2002 May;72(1–2):437–41. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0091305702007086>
448. Crivellato E, Beltrami CA, Mallardi F, Ribatti D. The mast cell: an active participant or an innocent bystander? *Histol Histopathol* [Internet]. 2004;19(1):259–70. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/14702194>
449. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, et al. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with β -amyloid[25–35]. *J Neuroimmunol* [Internet]. 1999 Jan;93(1–2):45–52. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S016557289800188X>
450. Block ML, Zecca L, Hong J-S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. *Nat Rev Neurosci* [Internet]. 2007 Jan;8(1):57–69. Available from: <http://www.nature.com/articles/nrn2038>
451. Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer’s disease. *J Neuroinflammation* [Internet]. 2006 Nov 9;3:30. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17094809>
452. Akundi RS, Candelario-Jalil E, Hess S, Hüll M, Lieb K, Gebicke-Haerter PJ, et al. Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. *Glia* [Internet]. 2005 Aug 15;51(3):199–208. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/glia.20198>
453. Ciallella JR, Saporito M, Lund S, Leist M, Hasseldam H, McGann N, et al. CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice. *Eur J Pharmacol* [Internet]. 2005 May 16;515(1–3):179–87. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15904918>
454. Lund S, Porzgen P, Mortensen AL, Hasseldam H, Bozyczko-Coyne D, Morath S, et al. Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. *J Neurochem* [Internet]. 2005 Feb 21;92(6):1439–51. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2005.03014.x>
455. Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S, et al. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. *Glia* [Internet]. 2005 May;50(3):235–46. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/glia.20173>
456. Zhu J, Qu C, Lu X, Zhang S. Activation of Microglia by Histamine and Substance P. *Cell Physiol Biochem* [Internet]. 2014;34(3):768–80. Available from: <https://www.karger.com/Article/FullText/363041>
457. Medina MÁ, Quesada AR, Núñez de Castro I, Sánchez-Jiménez F. Histamine, polyamines, and cancer. *Biochem Pharmacol* [Internet]. 1999 Jun;57(12):1341–4. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0006295299000052>
458. Saligrama N, Noubade R, Case LK, del Rio R, Teuscher C. Combinatorial roles for histamine H1-H2 and H3-H4 receptors in autoimmune inflammatory disease of the central nervous system. *Eur J Immunol* [Internet]. 2012 Jun;42(6):1536–46. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/eji.201141859>
459. Croyal M, Dauvilliers Y, Labeeuw O, Capet M, Schwartz JC, Robert P. Histamine and tele-methylhistamine quantification in cerebrospinal fluid from narcoleptic subjects by liquid chromatography tandem mass spectrometry with precolumn derivatization. *Anal Biochem*. 2011;409(1):28–36.
460. Anichtchik O V., Rinne JO, Kalimo H, Panula P. An altered histaminergic innervation of the substantia nigra in Parkinson’s disease. *Exp Neurol*. 2000;163(1):20–30.
461. Panula P, Nuutinen S. The histaminergic network in the brain: Basic organization and role in disease. *Nat Rev Neurosci* [Internet]. 2013;14(7):472–87. Available from: <http://dx.doi.org/10.1038/nrn3526>
462. Cacabelos R, Yamatodani A, Niigawa H, Hariguchi S, Tada K, Nishimura T, et al. Brain histamine in Alzheimer’s disease. *Methods Find Exp Clin Pharmacol* [Internet]. 1989 May;11(5):353–60. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2755282>
463. Rocha SM, Pires J, Esteves M, Graça B, Bernardino L. Histamine: a new immunomodulatory player in the neuron-glia crosstalk. *Front Cell Neurosci* [Internet]. 2014 Apr 30;8. Available from: <http://journal.frontiersin.org/article/10.3389/fncel.2014.00120/abstract>
464. Hu W, Chen Z. The roles of histamine and its receptor ligands in central nervous system disorders: An update. *Pharmacol Ther* [Internet]. 2017 Jul;175:116–32. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0163725817300633>
465. Rocha SM, Saraiva T, Cristóvão AC, Ferreira R, Santos T, Esteves M, et al. Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation. *J Neuroinflammation* [Internet]. 2016;13(1):1–16. Available from: <http://dx.doi.org/10.1186/s12974-016-0600-0>
466. Parsons ME, Ganellin CR. Histamine and its receptors. *Br J Pharmacol* [Internet]. 2006 Jan;147(S1):S127–35. Available from: <http://doi.wiley.com/10.1038/sj.bjp.0706440>
467. Shan L, Swaab DF, Bao A-M. Neuronal histaminergic system in aging and age-related neurodegenerative disorders. *Exp Gerontol* [Internet]. 2013 Jul;48(7):603–7. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0531556512002276>

468. Shan L, Bao A-M, Swaab DF. The human histaminergic system in neuropsychiatric disorders. *Trends Neurosci* [Internet]. 2015 Mar;38(3):167–77. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0166223614002367>
469. Shan L, Bossers K, Luchetti S, Balesar R, Lethbridge N, Chazot PL, et al. Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study. *Neurobiol Aging* [Internet]. 2012 Jul;33(7):1488.e1-1488.e13. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0197458011004477>
470. Shan L, Bossers K, Unmehopa U, Bao A-M, Swaab DF. Alterations in the histaminergic system in Alzheimer's disease: a postmortem study. *Neurobiol Aging* [Internet]. 2012 Nov;33(11):2585–98. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0197458011005719>
471. Shan L, Liu C-Q, Balesar R, Hofman MA, Bao A-M, Swaab DF. Neuronal histamine production remains unaltered in Parkinson's disease despite the accumulation of Lewy bodies and Lewy neurites in the tuberomammillary nucleus. *Neurobiol Aging* [Internet]. 2012 Jul;33(7):1343–4. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0197458011000066>
472. Haas HL, Panula P. Histamine receptors. *Neuropharmacology* [Internet]. 2016 Jul;106:1–2. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0028390816301435>
473. Ferreira R, Santos T, Gonçalves J, Baltazar G, Ferreira L, Agasse F, et al. Histamine modulates microglia function. *J Neuroinflammation* [Internet]. 2012 Dec 8;9(1):90. Available from: <https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-90>
474. Zhang W, Zhang X, Zhang Y, Qu C, Zhou X, Zhang S. Histamine Induces Microglia Activation and the Release of Proinflammatory Mediators in Rat Brain Via H1R or H4R. *J Neuroimmune Pharmacol*. 2020;15(2):280–91.
475. Theoharides TC. Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. *Front Neurosci* [Internet]. 2015;9. Available from: <http://journal.frontiersin.org/Article/10.3389/fnins.2015.00225/abstract>
476. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. *Prog Neurobiol* [Internet]. 2001 Apr;63(6):637–72. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0301008200000393>
477. Kato H, Niimi M, Yamamoto Y, Kawamura T, Morimoto-Ishizuka T, Sawada M, et al. Histamine production by cultured microglial cells of the mouse. *Neurosci Lett* [Internet]. 2001 Jun;305(3):181–4. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0304394001018353>
478. Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. *Trends Pharmacol Sci* [Internet]. 2011 Apr;32(4):242–9. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165614711000046>
479. Watanabe T, Taguchi Y, Shiosaka S, Tanaka J, Kubota H, Terano Y, et al. Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. *Brain Res* [Internet]. 1984 Mar;295(1):13–25. Available from: <https://linkinghub.elsevier.com/retrieve/pii/0006899384908114>
480. Panula P, Yang HY, Costa E. Histamine-containing neurons in the rat hypothalamus. *Proc Natl Acad Sci* [Internet]. 1984 Apr 1;81(8):2572–6. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.81.8.2572>
481. Alvarez XA, Franco A, Fernández-Novoa L, Cacabelos R. Effects of neurotoxic lesions in histaminergic neurons on brain tumor necrosis factor levels. *Agents Actions* [Internet]. 1994 Jun;41(S1):C70–2. Available from: <http://link.springer.com/10.1007/BF02007772>
482. Fernández-Novoa L, Franco-Maside A, Alvarez XA, Cacabelos R. Effects of histamine and α -fluoromethylhistidine on brain tumor necrosis factor levels in rats. *Inflamm Res* [Internet]. 1995 Jan;44(1):55–7. Available from: <http://link.springer.com/10.1007/BF01630488>
483. Alvarez XA, Franco A, Fernández-Novoa L, Cacabelos R. Blood levels of histamine, IL-1 β , and TNF- α in patients with mild to moderate alzheimer disease. *Mol Chem Neurobiol* [Internet]. 1996 Oct;29(2–3):237–52. Available from: <http://link.springer.com/10.1007/BF02815005>
484. Sierra A, Abiega O, Shahraz A, Neumann H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. *Front Cell Neurosci* [Internet]. 2013;7. Available from: <http://journal.frontiersin.org/article/10.3389/fncel.2013.00006/abstract>
485. Peterson LJ, Flood PM. Oxidative Stress and Microglial Cells in Parkinson's Disease. *Mediators Inflamm* [Internet]. 2012;2012:1–12. Available from: <http://www.hindawi.com/journals/mi/2012/401264/>
486. Mossakowski AA, Pohlan J, Bremer D, Lindquist R, Millward JM, Bock M, et al. Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation. *Acta Neuropathol* [Internet]. 2015 Dec 31;130(6):799–814. Available from: <http://link.springer.com/10.1007/s00401-015-1497-x>
487. Cheret C, Gervais A, Lelli A, Colin C, Amar L, Ravassard P, et al. Neurotoxic Activation of Microglia Is Promoted by a Nox1-Dependent NADPH Oxidase. *J Neurosci* [Internet]. 2008 Nov 12;28(46):12039–51. Available from: <https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.3568-08.2008>
488. Fernandez-Novoa L. Histamine function in brain disorders. *Behav Brain Res* [Internet]. 2001 Oct 15;124(2):213–33. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0166432801002157>
489. Cacabelos R, Torrellas C, Fernández-Novoa L, Aliev G. Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection. *Curr Pharm Des* [Internet]. 2016 Jan 27;22(7):819–48. Available from: <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1381-6128&volume=22&issue=7&page=819>
490. Rinne JO, Anichtchik O V., Eriksson KS, Kaslin J, Tuomisto L, Kalimo H, et al. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. *J Neurochem* [Internet]. 2002 May 21;81(5):954–60. Available from: <http://doi.wiley.com/10.1046/j.1471-4159.2002.00871.x>
491. Binukumar BK, Bal A, Gill KD. Chronic Dichlorvos Exposure: Microglial Activation, Proinflammatory Cytokines and Damage to Nigrostriatal Dopaminergic System. *NeuroMolecular Med* [Internet]. 2011 Dec 4;13(4):251–65. Available from: <http://link.springer.com/10.1007/s12017-011-8156-8>
492. Vizuete ML, Merino M, Venero JL, Santiago M, Cano J, Machado A. Histamine Infusion Induces a Selective Dopaminergic Neuronal Death Along with an Inflammatory Reaction in Rat Substantia Nigra. *J Neurochem* [Internet]. 2002 Jan 4;75(2):540–52. Available from: <http://doi.wiley.com/10.1046/j.1471-4159.2000.0750540.x>
493. Lu Z, Elliott MR, Chen Y, Walsh JT, Klibanov AL, Ravichandran KS, et al. Phagocytic activity of neuronal

- progenitors regulates adult neurogenesis. *Nat Cell Biol* [Internet]. 2011 Sep;13(9):1076–83. Available from: <http://www.nature.com/articles/ncb2299>
494. Arai H, Furuya T, Yasuda T, Miura M, Mizuno Y, Mochizuki H. Neurotoxic Effects of Lipopolysaccharide on Nigral Dopaminergic Neurons Are Mediated by Microglial Activation, Interleukin-1 β , and Expression of Caspase-11 in Mice. *J Biol Chem* [Internet]. 2004 Dec;279(49):51647–53. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0021925820694625>
 495. Barkauskas DS, Dixon Dorand R, Myers JT, Evans TA, Barkauskas KJ, Askew D, et al. Focal transient CNS vessel leak provides a tissue niche for sequential immune cell accumulation during the asymptomatic phase of EAE induction. *Exp Neurol* [Internet]. 2015 Apr;266:74–85. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0014488615000412>
 496. Pozzi D, Menna E, Canzi A, Desiato G, Mantovani C, Matteoli M. The Communication Between the Immune and Nervous Systems: The Role of IL-1 β in Synaptopathies. *Front Mol Neurosci* [Internet]. 2018 Apr 5;11. Available from: <http://journal.frontiersin.org/article/10.3389/fnmol.2018.00111/full>
 497. Barata-Antunes S, Cristóvão AC, Pires J, Rocha SM, Bernardino L. Dual role of histamine on microglia-induced neurodegeneration. *Biochim Biophys Acta - Mol Basis Dis* [Internet]. 2017 Mar;1863(3):764–9. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0925443916303532>
 498. Fan L, Young PR, Barone FC, Feuerstein GZ, Smith DH, McIntosh TK. Experimental brain injury induces differential expression of tumor necrosis factor- α mRNA in the CNS. *Mol Brain Res* [Internet]. 1996 Mar;36(2):287–91. Available from: <https://linkinghub.elsevier.com/retrieve/pii/0169328X9500274V>
 499. Shohami E, Novikov M, Bass R, Yamin A, Gallily R. Closed Head Injury Triggers Early Production of TNF α and IL-6 by Brain Tissue. *J Cereb Blood Flow Metab* [Internet]. 1994 Jul 28;14(4):615–9. Available from: <http://journals.sagepub.com/doi/10.1038/jcbfm.1994.76>
 500. Helmy A, De Simoni M-G, Guilfoyle MR, Carpenter KLH, Hutchinson PJ. Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. *Prog Neurobiol* [Internet]. 2011 Nov;95(3):352–72. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0301008211001638>
 501. Schmidt OI, Heyde CE, Ertel W, Stahel PF. Closed head injury—an inflammatory disease? *Brain Res Rev* [Internet]. 2005 Apr;48(2):388–99. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165017304002061>
 502. Guido S, Sebastian J, Schroeter M. Detrimental and Beneficial Effects of Injury-Induced Inflammation and Cytokine Expression in the Nervous System. In 2003. p. 87–113. Available from: http://link.springer.com/10.1007/978-1-4615-0123-7_3
 503. A. Frankola K, H. Greig N, Luo W, Tweedie D. Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. *CNS Neurol Disord - Drug Targets* [Internet]. 2011 May 1;10(3):391–403. Available from: <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5273&volume=10&issue=3&page=391>
 504. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. *Pharmacol Ther* [Internet]. 2010 Dec;128(3):519–48. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S016372581000166X>
 505. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. *J Neuroinflammation* [Internet]. 2008;5(1):45. Available from: <http://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-5-45>
 506. Frugier T, Morganti-Kossmann MC, O'Reilly D, McLean CA. In Situ Detection of Inflammatory Mediators in Post Mortem Human Brain Tissue after Traumatic Injury. *J Neurotrauma* [Internet]. 2010 Mar;27(3):497–507. Available from: <http://www.liebertpub.com/doi/10.1089/neu.2009.1120>
 507. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. Cytokine production in the brain following closed head injury: dexamethasone (DEX) is a novel TNF- α inhibitor and an effective neuroprotectant. *J Neuroimmunol* [Internet]. 1997 Feb;72(2):169–77. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165572896001816>
 508. Yang J, You Z, Kim H-H, Hwang S-K, Khuman J, Guo S, et al. Genetic Analysis of the Role of Tumor Necrosis Factor Receptors in Functional Outcome after Traumatic Brain Injury in Mice. *J Neurotrauma* [Internet]. 2010 Jun;27(6):1037–46. Available from: <http://www.liebertpub.com/doi/10.1089/neu.2009.1229>
 509. Lu J. Systemic inflammatory response following acute traumatic brain injury. *Front Biosci* [Internet]. 2009;Volume(14):3795. Available from: <https://fbscience.com/Landmark/articles/10.2741/3489>
 510. Tuttolomondo A, Pecoraro R, Pinto A. Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. *Drug Des Devel Ther* [Internet]. 2014 Nov;2221. Available from: <http://www.dovepress.com/studies-of-selective-tnf-inhibitors-in-the-treatment-of-brain-injury-f-peer-reviewed-article-DDDT>
 511. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor- α . *Cerebrovasc Brain Metab Rev* [Internet]. 1994;6(4):341–60. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7880718>
 512. ARVIN B, NEVILLE LF, BARONE FC, FEUERSTEIN GZ. The Role of Inflammation and Cytokines in Brain Injury. *Neurosci Biobehav Rev* [Internet]. 1996 Jan;20(3):445–52. Available from: <https://linkinghub.elsevier.com/retrieve/pii/0149763495000267>
 513. Fillit H, Ding W, Buee L, Kalman J, Altstiel L, Lawlor B, et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. *Neurosci Lett* [Internet]. 1991 Aug;129(2):318–20. Available from: <https://linkinghub.elsevier.com/retrieve/pii/030439409190490K>
 514. Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF- α and blood-brain barrier damage. *J Neuroimmunol* [Internet]. 1993 Mar;43(1–2):15–21. Available from: <https://linkinghub.elsevier.com/retrieve/pii/016557289390070F>
 515. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor- α (TNF- α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. *Neurosci Lett* [Internet]. 1994 Jan;165(1–2):208–10. Available from: <https://linkinghub.elsevier.com/retrieve/pii/0304394094907463>
 516. Waage A, Halstensen A, Shalaby R, Brandtzaeg P, Kierulf P, Espevik T. Local production of tumor necrosis factor

- alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. *J Exp Med* [Internet]. 1989 Dec 1;170(6):1859–67. Available from: <https://rupress.org/jem/article/170/6/1859/50184/Local-production-of-tumor-necrosis-factor-alpha>
517. Merrill JE, Chen ISY. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. *FASEB J* [Internet]. 1991 Jul;5(10):2391–7. Available from: <https://onlinelibrary.wiley.com/doi/10.1096/fasebj.5.10.2065887>
518. Tarlow MJ, Jenkins R, Comis SD, Osborne MP, Stephens S, Stanley P, et al. Ependymal cells of the choroid plexus express tumour necrosis factor- α . *Neuropathol Appl Neurobiol* [Internet]. 1993 Aug;19(4):324–8. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2990.1993.tb00447.x>
519. Chung IY, Benveniste EN. Tumor necrosis factor- α production by astrocytes. Induction by lipopolysaccharide, IFN- γ , and IL-1 β . *J Immunol* [Internet]. 1990 Apr 15;144(8):2999–3007. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2109008>
520. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. *Proc Natl Acad Sci* [Internet]. 1989 Aug 1;86(16):6348–52. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.86.16.6348>
521. Ganter S, Northoff H, Männel D, Gebicke-Härter PJ. Growth control of cultured microglia. *J Neurosci Res* [Internet]. 1992 Oct;33(2):218–30. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jnr.490330205>
522. Buttini M, Appel K, Sauter A, Gebicke-Haerter P-J, Boddeke HWGM. Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. *Neuroscience*. 1996 Mar;71(1):1–16.
523. Breder CD, Hazuka C, Ghayur T, Klug C, Huginin M, Yasuda K, et al. Regional induction of tumor necrosis factor alpha expression in the mouse brain after systemic lipopolysaccharide administration. *Proc Natl Acad Sci* [Internet]. 1994 Nov 22;91(24):11393–7. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.91.24.11393>
524. Tchelingirian J-L, Quinero J, Booss J, Jacque C. Localization of TNF α and IL-1 α immunoreactivities in striatal neurons after surgical injury to the hippocampus. *Neuron* [Internet]. 1993 Feb;10(2):213–24. Available from: <https://linkinghub.elsevier.com/retrieve/pii/089662739390312F>
525. Pera J, Zawadzka M, Kaminska B, Szczudlik A. Influence of chemical and ischemic preconditioning on cytokine expression after focal brain ischemia. *J Neurosci Res* [Internet]. 2004 Oct 1;78(1):132–40. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jnr.20232>
526. MacEwan DJ. TNF ligands and receptors - a matter of life and death. *Br J Pharmacol*. 2002 Feb;135(4):855–75.
527. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. *Cell Death Differ* [Internet]. 2003 Jan 25;10(1):45–65. Available from: <http://www.nature.com/articles/4401189>
528. Chen G, Goeddel D V. TNF-R1 Signaling: A Beautiful Pathway. *Science* (80-) [Internet]. 2002 May 31;296(5573):1634–5. Available from: <https://www.science.org/doi/10.1126/science.1071924>
529. Shohami E, Bass R, Wallach D, Yamin A, Gallily R. Inhibition of Tumor Necrosis Factor Alpha (TNF α) Activity in Rat Brain is Associated with Cerebroprotection after Closed Head Injury. *J Cereb Blood Flow Metab* [Internet]. 1996 May 31;16(3):378–84. Available from: <http://journals.sagepub.com/doi/10.1097/00004647-199605000-00004>
530. Scherbel U, Raghupathi R, Nakamura M, Saatman KE, Trojanowski JQ, Neugebauer E, et al. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. *Proc Natl Acad Sci* [Internet]. 1999 Jul 20;96(15):8721–6. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.96.15.8721>
531. Sullivan PG, Bruce-Keller AJ, Rabchevsky AG, Christakos S, Clair DK St., Mattson MP, et al. Exacerbation of Damage and Altered NF- κ B Activation in Mice Lacking Tumor Necrosis Factor Receptors after Traumatic Brain Injury. *J Neurosci* [Internet]. 1999 Aug 1;19(15):6248–56. Available from: <https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.19-15-06248.1999>
532. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. *Nat Med* [Internet]. 2002 Dec;8(12):1363–8. Available from: <http://www.nature.com/articles/nm1202-1363>
533. Shohami E. Dual role of tumor necrosis factor alpha in brain injury. *Cytokine Growth Factor Rev* [Internet]. 1999 Jun;10(2):119–30. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1359610199000088>
534. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2. *J Neurosci* [Internet]. 2002 Apr 1;22(7):RC216–RC216. Available from: <https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.22-07-j0001.2002>
535. Balosso S, Ravizza T, Perego C, Peschon J, Campbell IL, De Simoni MG, et al. Tumor necrosis factor- α inhibits seizures in mice via p75 receptors. *Ann Neurol* [Internet]. 2005 Jun;57(6):804–12. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/ana.20480>
536. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. *Proc Natl Acad Sci* [Internet]. 2008 Apr 22;105(16):6185–90. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.0801447105>
537. Taoufik E, Valable S, Muller GJ, Roberts ML, Divoux D, Tinel A, et al. FLIPL Protects Neurons against In Vivo Ischemia and In Vitro Glucose Deprivation-Induced Cell Death. *J Neurosci* [Internet]. 2007 Jun 20;27(25):6633–46. Available from: <https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.1091-07.2007>
538. Lambertsen KL, Clausen BH, Babcock AA, Gregersen R, Fenger C, Nielsen HH, et al. Microglia Protect Neurons against Ischemia by Synthesis of Tumor Necrosis Factor. *J Neurosci* [Internet]. 2009 Feb 4;29(5):1319–30. Available from: <https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.5505-08.2009>
539. Longhi L, Perego C, Ortolano F, Aresi S, Fumagalli S, Zanier ER, et al. Tumor Necrosis Factor in Traumatic Brain Injury: Effects of Genetic Deletion of p55 or p75 Receptor. *J Cereb Blood Flow Metab* [Internet]. 2013 Aug 24;33(8):1182–9. Available from: <http://journals.sagepub.com/doi/10.1038/jcbfm.2013.65>
540. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, et al. Tumor Necrosis Factor- α . *Stroke* [Internet]. 1997 Jun;28(6):1233–44. Available from: <https://www.ahajournals.org/doi/10.1161/01.STR.28.6.1233>
541. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF Receptor Superfamilies. *Cell* [Internet]. 2001 Feb;104(4):487–501. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0092867401002379>
542. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, et al. Targeted mutation in the Fas gene

- causes hyperplasia in peripheral lymphoid organs and liver. *Nat Genet* [Internet]. 1995 Nov;11(3):294–300. Available from: <http://www.nature.com/articles/ng1195-294>
543. Berrrrrphol D, You Z, Lo EH, Kim H-H, Whalen MJ. TNF Alpha and Fas Mediate Tissue Damage and Functional Outcome after Traumatic Brain Injury in Mice. *J Cereb Blood Flow Metab* [Internet]. 2007 Nov 4;27(11):1806–18. Available from: <http://journals.sagepub.com/doi/10.1038/sj.jcbfm.9600487>
544. Robertson J, Beaulieu J-M, Doroudchi MM, Durham HD, Julien J-P, Mushynski WE. Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor- α . *J Cell Biol* [Internet]. 2001 Oct 15;155(2):217–26. Available from: <https://rupress.org/jcb/article/155/2/217/43982/Apoptotic-death-of-neurons-exhibiting-peripherin>
545. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF- α Pretreatment Induces Protective Effects against Focal Cerebral Ischemia in Mice. *J Cereb Blood Flow Metab* [Internet]. 1997 May 31;17(5):483–90. Available from: <http://journals.sagepub.com/doi/10.1097/00004647-199705000-00001>
546. Pober JS, Cotran RS. Cytokines and endothelial cell biology. *Physiol Rev* [Internet]. 1990 Apr 1;70(2):427–51. Available from: <https://www.physiology.org/doi/10.1152/physrev.1990.70.2.427>
547. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. *J Immunol* [Internet]. 1990 Jan 1;144(1):129–35. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2104886>
548. Sedgwick JD, Riminton DS, Cyster JG, Körner H. Tumor necrosis factor: a master-regulator of leukocyte movement. *Immunol Today* [Internet]. 2000 Mar;21(3):110–3. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S016756999901573X>
549. Leon LR. Invited Review: Cytokine regulation of fever: studies using gene knockout mice. *J Appl Physiol* [Internet]. 2002 Jun 1;92(6):2648–55. Available from: <https://www.physiology.org/doi/10.1152/jappphysiol.01005.2001>
550. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, et al. Control of Synaptic Strength by Glial TNF α . *Science* (80-) [Internet]. 2002 Mar 22;295(5563):2282–5. Available from: <https://www.science.org/doi/10.1126/science.1067859>
551. Pickering M, Cumiskey D, O'Connor JJ. Actions of TNF- α on glutamatergic synaptic transmission in the central nervous system. *Exp Physiol* [Internet]. 2005 Sep;90(5):663–70. Available from: <http://doi.wiley.com/10.1113/expphysiol.2005.030734>
552. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF- α . *Nature* [Internet]. 2006 Apr 20;440(7087):1054–9. Available from: <http://www.nature.com/articles/nature04671>
553. Stellwagen D. Differential Regulation of AMPA Receptor and GABA Receptor Trafficking by Tumor Necrosis Factor-. *J Neurosci* [Internet]. 2005 Mar 23;25(12):3219–28. Available from: <https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.4486-04.2005>
554. Weber C, Erl W, Pietsch A, Ströbel M, Ziegler-Heitbrock HW, Weber PC. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. *Arterioscler Thromb A J Vasc Biol* [Internet]. 1994 Oct;14(10):1665–73. Available from: <https://www.ahajournals.org/doi/10.1161/01.ATV.14.10.1665>
555. Ross SA, Halliday MI, Campbell GC, Byrnes DP, Rowlands BJ. The presence of tumour necrosis factor in CSF and plasma after severe head injury. *Br J Neurosurg* [Internet]. 1994 Jan 6;8(4):419–25. Available from: <http://www.tandfonline.com/doi/full/10.3109/02688699408995109>
556. Baratz R, Tweedie D, Wang J-Y, Rubovitch V, Luo W, Hoffer BJ, et al. Transiently lowering tumor necrosis factor- α synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice. *J Neuroinflammation* [Internet]. 2015 Dec 7;12(1):45. Available from: <https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0237-4>
557. Rothwell NJ. Cytokines - killers in the brain? *J Physiol* [Internet]. 1999 Jan 8;514(1):3–17. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1469-7793.1999.003af.x>
558. Hayakata T, Shiozaki T, Tasaki O, Ikegawa H, Inoue Y, Toshiyuki F, et al. CHANGES IN CSF S100B AND CYTOKINE CONCENTRATIONS IN EARLY-PHASE SEVERE TRAUMATIC BRAIN INJURY. *Shock* [Internet]. 2004 Aug;22(2):102–7. Available from: <http://journals.lww.com/00024382-200408000-00002>
559. Shiozaki T, Hayakata T, Tasaki O, Hosotubo H, Fuijita K, Mouri T, et al. CEREBROSPINAL FLUID CONCENTRATIONS OF ANTI-INFLAMMATORY MEDIATORS IN EARLY-PHASE SEVERE TRAUMATIC BRAIN INJURY. *Shock* [Internet]. 2005 May;23(5):406–10. Available from: <http://journals.lww.com/00024382-200505000-00003>
560. Stein DM, Lindell A, Murdock KR, Kufera JA, Menaker J, Keledjian K, et al. Relationship of Serum and Cerebrospinal Fluid Biomarkers With Intracranial Hypertension and Cerebral Hypoperfusion After Severe Traumatic Brain Injury. *J Trauma Inj Infect Crit Care* [Internet]. 2011 May;70(5):1096–103. Available from: <https://journals.lww.com/00005373-201105000-00012>
561. Hergenroeder GW, Redell JB, Moore AN, Dash PK. Biomarkers in the Clinical Diagnosis and Management of Traumatic Brain Injury. *Mol Diagn Ther* [Internet]. 2008 Nov 16;12(6):345–58. Available from: <http://link.springer.com/10.1007/BF03256301>
562. Pelinka LE. Serum markers of severe traumatic brain injury: Are they useful? *Indian J Crit Care Med*. 2005;8(3):190–3.
563. LIU C, TANG J. Expression levels of tumor necrosis factor- α and the corresponding receptors are correlated with trauma severity. *Oncol Lett* [Internet]. 2014 Dec;8(6):2747–51. Available from: <https://www.spandidos-publications.com/10.3892/ol.2014.2575>
564. Hevesi D. Allergy Reliever Dies. *New York times*. 2008;91(George Rieveschl).
565. Domino EF. History of modern psychopharmacology: a personal view with an emphasis on antidepressants. *Psychosom Med*. 61(5):591–8.
566. Adawi Awdish RL, Whitmill M, Coba V, Killu K. SEROTONIN REUPTAKE INHIBITION BY DIPHENHYDRAMINE AND CONCOMITANT LINEZOLID USE CAN RESULT IN SEROTONIN SYNDROME. *Chest*. 2008 Oct;134(4):4C.
567. FDA. Difenhidramin Hydrochloride injection. USP.

- 2013;(https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/0915261bl.pdf).
568. National Center for Biotechnology Information. Diphenhydramine hydrochloride. Natl Cent Biotechnol Inf. 2004;8980(PubChem Compound Summary for CID).
569. Skidgel R.A. - Kaplan A.P. - Erdos E.G. Histamine, bradykinin, and their antagonists. Goodman Gilman's Pharmacol Basis Ther 12e McGraw Hill. 2015;12e Eds(https://accessmedicine.mhmedical.com/content.aspx?bookid=1613§ionid=102160870).
570. FDA. FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER D - DRUGS FOR HUMAN USE. Code Fed Regul. Volume 5(Title 21,) [CITE: 21CFR341.72).
571. Church M, Church D. Pharmacology of antihistamines. Indian J Dermatol. 2013;58(3):219.
572. Simons FER, Simons KJ. Histamine and H1-antihistamines: Celebrating a century of progress. J Allergy Clin Immunol. 2011 Dec;128(6):1139-1150.e4.
573. Bolser DC. Older-Generation Antihistamines and Cough Due to Upper Airway Cough Syndrome (UACS): Efficacy and Mechanism. Lung. 2008 Feb 2;186(S1):74-7.
574. Drugbanks. Difenhidramin. 2018;(https://www.drugbank.ca/drugs/DB01075).
575. Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG. Pharmacokinetics of diphenhydramine in man. J Pharmacokinet Biopharm. 1975 Jun 17;3(3):159-70.
576. Blyden GT, Greenblatt DJ, Scavone JM, Shader RI. Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration. J Clin Pharmacol. 1986 Sep 10;26(7):529-33.
577. Scavone JM, Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetics and Pharmacodynamics of Diphenhydramine 25 mg in Young and Elderly Volunteers. J Clin Pharmacol. 1998 Jul;38(7):603-9.
578. MIMS Indonesia. Difenhidramin. 2017;(http://www.mims.com/indonesia/drug/info/Difenhidramin?mtype=generic).
579. Simons KJ, Watson WTA, Martin TJ, Chen MXY, Simons FER. Diphenhydramine: Pharmacokinetics and Pharmacodynamics in Elderly Adults, Young Adults, and Children. J Clin Pharmacol. 1990 Jul;30(7):665-71.
580. Kesiova M, Alexandrova A, Yordanova N, Kirkova M, Todorov S. Effects of diphenhydramine and famotidine on lipid peroxidation and activities of antioxidant enzymes in different rat tissues. Pharmacol Rep. 58(2):221-8.
581. Bañuelos-Cabrera I, Valle-Dorado MG, Aldana BI, Orozco-Suárez SA, Rocha L. Role of Histaminergic System in Blood-Brain Barrier Dysfunction Associated with Neurological Disorders. Arch Med Res. 2014 Nov;45(8):677-86.
582. Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, Karlsson L, et al. Histamine H₄ receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol. 2004 May;142(1):161-71.
583. Barnard R, Barnard A, Salmon G, Liu W, Sreckovic S. Histamine-induced actin polymerization in human eosinophils: An imaging approach for histamine H₄ receptor. Cytom Part A. 2008 Apr;73A(4):299-304.
584. Bocsan IC, Muntean IA, Vesa S, Deleanu D, Buzoianu AD. H1 Antihistamines' effect on pro-inflammatory Cytokines in allergic rhinitis to house dust mites. Clin Ther [Internet]. 2015 Aug;37(8):e106-7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0149291815006153
585. Küsters S, Schuligoi R, Hüttenbrink K-BB, Rudert J, Wachs A, Szelenyi I, et al. Effects of Antihistamines on Leukotriene and Cytokine Release from Dispersed Nasal Polyp Cells. Arzneimittelforschung [Internet]. 2011 Dec 26 [cited 2021 Dec 5];52(02):97-102. Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0031-1299863
586. Bissonnette EY. Histamine inhibits tumor necrosis factor alpha release by mast cells through H2 and H3 receptors. Am J Respir Cell Mol Biol [Internet]. 1996 [cited 2021 Dec 5];14(6):620-6. Available from: https://pubmed.ncbi.nlm.nih.gov/8652190/
587. MERLOS M. 191 Inhibitory effect of rupatadine on TNF-alpha release from human monocytes and mast cell line HMC-1. J Allergy Clin Immunol [Internet]. 2000 Jan;105(1):S62. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0091674900906225
588. Levy D, Edut S, Baraz-Goldstein R, Rubovitch V, Defrin R, Bree D, et al. Responses of dural mast cells in concussive and blast models of mild traumatic brain injury in mice: Potential implications for post-traumatic headache. Cephalalgia [Internet]. 2016 Sep 20;36(10):915-23. Available from: http://journals.sagepub.com/doi/10.1177/0333102415617412
589. Schieber M, Chandel NS. ROS Function in Redox Signaling and Oxidative Stress. Curr Biol [Internet]. 2014 May;24(10):R453-62. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960982214003261
590. Ray PD, Huang B-W, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal [Internet]. 2012 May;24(5):981-90. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0898656812000137
591. Govindaraj J, Emmadi P, Deepalakshmi, Rajaram V, Prakash G, Puvanakrishnan R. Protective effect of proanthocyanidins on endotoxin induced experimental periodontitis in rats. Indian J Exp Biol [Internet]. 2010 Feb;48(2):133-42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20455322
592. Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci [Internet]. 2005 Nov;6B(11):1045-56. Available from: http://www.zju.edu.cn/jzus/article.php?doi=10.1631/jzus.2005.B1045
593. Chen C, Khismatullin DB. Synergistic effect of histamine and TNF- α on monocyte adhesion to vascular endothelial cells. Inflammation. 2013;36(2):309-19.
594. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand. 2001;173(1):35-43.
595. Yago T, Shao B, Miner JJ, Yao L, Klopocki AG, Maeda K, et al. E-selectin engages PSGL-1 and CD44 through a common signaling pathway to induce integrin α L β 2-mediated slow leukocyte rolling. Blood. 2010;116(3):485-94.
596. Green CE, Pearson DN, Camphausen RT, Staunton DE, Simon SI. Shear-Dependent Capping of L-Selectin and P-Selectin Glycoprotein Ligand 1 by E-Selectin Signals Activation of High-Avidity β 2 -Integrin on Neutrophils . J Immunol. 2004;172(12):7780-90.
597. Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OAR, Malolepszy J, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature. 2001;413(6854):420-5.

598. Jiyeon Yang, Lixiao Zhang, Caijia Yu X-FY and HW. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. *Science* (80-). 2014;312(5782):1868–9.
599. Wang KY, Arima N, Higuchi S, Shimajiri S, Tanimoto A, Murata Y, et al. Switch of histamine receptor expression from H2 to H1 during differentiation of monocytes into macrophages. *FEBS Lett.* 2000;473(3):345–8.
600. Triggiani M, Petraroli A, Loffredo S, Frattini A, Granata F, Morabito P, et al. Differentiation of monocytes into macrophages induces the upregulation of histamine H1 receptor. *J Allergy Clin Immunol.* 2007;119(2):472–81.
601. Marmarou A, Abd-Elfattah Foda MA, Van den Brink W, Campbell J, Kita H, Demetriadou K. A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. *J Neurosurg.* 1994;80(2):291–300.

LAMPIRAN 1 : Data Mentah Berat Badan Tikus

No. Sampel	BERAT BADAN TIKUS	
	Kelompok 1 (Diphenhydramine) gram	Kelompok 2 (Placebo) gram
1	168	159
2	154	163
3	151	150
4	152	180
5	159	158
6	177	172
7	175	154
8	174	168
9	160	161
10	170	140
11	159	156

LAMPIRAN 2 : Data Mentah Hasil Penelitian Histamin Serum

KADAR HISTAMIN SERUM DARAH TIKUS η/ml			
Waktu Pemeriksaan	No. Sampel	Kelompok 1 (Diphenhydramine) ng/ml	Kelompok 2 (Placebo) ng/ml
Jam 0 (pre-perlakuan)	1	168,8609376	167,9284628
	2	117,1247404	120,4672843
	3	408,4360219	400,6294816
	4	98,98863011	97,53678917
	5	151,294997	149,2647892
30 menit pasca perlakuan TBI	1	186,9520332	267,0598819
	2	170,9818241	243,1505708
	3	181,6224581	254,8721966
	4	177,6594638	229,3767766
	5	186,5626555	222,9810196
2 jam pasca perlakuan TBI	1	112,6410424	320,6677959
	2	120,4659734	338,495167
	3	121,1532546	339,4629086
	4	127,272754	348,2169136
	5	123,261093	324,9903093
24 jam pasca perlakuan TBI	1	90,99243375	312,1165164
	2	104,1874916	311,4811801
	3	111,2399969	320,9685398
	4	94,5941734	324,0226431
	5	110,9861179	355,0661275

LAMPIRAN 3 : Data Mentah Hasil Penelitian TNF- α Serum

KADAR TNF-a SERUM DARAH TIKUS $\mu\text{g/ml}$			
Waktu Pemeriksaan	No. Sampel	Kelompok 1 (Diphenhydramine) $\mu\text{g/ml}$	Kelompok 2 (Placebo) $\mu\text{g/ml}$
Jam 0 (pre-perlakuan)	1	32,4099	30,4612
	2	27,2949	30,3301
	3	33,2163	31,7919
	4	21,3508	27,6801
	5	31,8501	23,4501
30 menit pasca perlakuan TBI	1	34,4240	33,4299
	2	30,6736	31,2612
	3	32,9943	37,0073
	4	38,4990	34,9256
	5	25,5761	34,5953
2 jam pasca perlakuan TBI	1	22,8145	35,4634
	2	24,4598	37,7988
	3	24,4465	45,1453
	4	23,6894	42,4620
	5	24,8345	44,9223
24 jam pasca perlakuan TBI	1	22,7785	35,4782
	2	22,4730	39,0061
	3	20,3530	41,6394
	4	22,1000	40,8282
	5	20,6786	39,1872

LAMPIRAN 4 : Data Mentah Hasil Penelitian *Brain Water Content (BWC)*

No	KELOMPOK 1 (DIPHEHYDRAMINE)			
	WET WEIGHT (WW) gram	DRY WEIGHT (DW) gram	WW-DW (gram)	BRAIN WATER CONTENT (%)
1	0,633	0,239	0,394	0,622432859
2	0,765	0,240	0,525	0,68627451
3	0,683	0,242	0,441	0,64568082
4	0,775	0,239	0,536	0,691612903
5	0,752	0,249	0,503	0,668882979
No	KELOMPOK 2 (PLACEBO)			
	WET WEIGHT (WW) gram	DRY WEIGHT (DW) gram	WW-DW (gram)	BRAIN WATER CONTENT (%)
1	1,386	0,235	1,151	0,83044733
2	1,364	0,242	1,122	0,822580645
3	1,365	0,223	1,142	0,836630037
4	1,379	0,232	1,147	0,831762146
5	1,338	0,243	1,095	0,81838565
No	KELOMPOK KONTROL (PRELAB)			
	WET WEIGHT (WW) gram	DRY WEIGHT (DW) gram	WW-DW (gram)	BRAIN WATER CONTENT (%)
1	0,396	0,23	0,166	0,419191919
2	0,503	0,241	0,262	0,520874751
3	0,418	0,232	0,186	0,444976077
4	0,42	0,235	0,185	0,44047619
5	0,507	0,242	0,265	0,522682446